2_test

PMC:4706832 / 10438-10442 JSON TXT

Discovery of potential ALK inhibitors by virtual screening approach Abstract Crizotinib is an anticancer drug used for the treatment of non-small cell lung cancer. Evidences available suggest that there is a development of an acquired resistance against crizotinib action due to the emergence of several mutations in the ALK gene. It is therefore necessary to develop potent anti-cancer drugs for the treatment of crizotinib resistance non-small cell lung cancer types. In the present study, a novel class of lead molecule was identified using virtual screening, molecular docking and molecular dynamic approach. The virtual screening analysis was done using PubChem database by employing crizotinib as query and the data reduction was carried out by using molecular docking techniques. The bioavailability of the lead compounds was examined with the help of Lipinski rule of five. The screened lead molecules were analyzed for toxicity profiles, drug-likeness and other physico-chemical properties of drugs by OSIRIS program. Finally, molecular dynamics simulation was also performed to validate the binding property of the lead compound. Our analysis clearly indicates that CID 11562217, a nitrile containing compound (pyrazole-substituted aminoheteroaryl), could be the potential ALK inhibitor certainly helpful to overcome the drug resistance in non-small cell lung cancer. Introduction Lung cancer is the prominent cause of cancer deaths in the world and a global issue to be addressed (Siegel et al. 2012). Lung cancer is broadly classified into two main types based upon their histology, which are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The most common forms of NSCLC are adenocarcinoma (ADC) and squamous cell carcinoma (SCC) (Skarda et al. 2008). Chromosomal rearrangements in the anaplastic lymphoma kinase (ALK) gene that codes for anaplastic lymphoma kinase has been identified as one of the causes of NSCLC. There are two types of tyrosine kinase, receptor and cytoplasmic tyrosine kinase. The ALK is a cytoplasmic tyrosine kinase where crizotinib (a potential anticancer drug used in the treatment of NSCLC) is bound. Chromosomal rearrangements involving the ALK gene occur in different malignant conditions, including anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) (Chiarle et al. 2008). These rearrangements lead to the expression of ALK fusion genes. ALK fusion gene possesses different properties from the two genes that it was originally derived from, can then code for the new ALK fusion protein, which is abnormally and constitutively activated. The new protein contains the tyrosine kinase domain of ALK and the coiled coil domain of EML4. The coiled coil domain of EML4 allows this protein to bind with other ALK fusion proteins and form dimerised and activated fusion proteins (Katayama et al. 2012). The most prevalent ALK fusion oncogene in NSCLC is the echinoderm microtubule-associated protein-like 4 (EML4)–ALK fusion gene and is present in 4–5 % of cases of NSCLC (Young et al. 2010). An inversion in the chromosome 2 brings together the 5′ end of the EML4 gene and the 3′ end of the ALK gene resulting in the formation of the EML4-ALK fusion gene (Shaw and Solomon 2011). The affected person tend to have typical clinical features like early age of onset, little or absence of any smoking history (Shaw et al. 2009). Some of the drugs commonly used for the chemotherapeutic treatment of lung cancer are Bevacizumab, Carboplatin, Cisplatin, Crizotinib, Docetaxel, Erlotinib, Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, and Vinorelbine. Targeted drug therapy is used against NSCLC of which tyrosine kinase inhibitors are amongst the best method in treatment methodology. In particular, crizotinib is one such tyrosine kinase inhibitor which is the first drug to have gained FDA approval for the treatment of NSCLC in 2011 (Ou, 2011). Although crizotinib has proved itself as an efficient counter to ALK type NSCLC, acquired resistance has made its beneficial effects temporary and has emerged as a major roadblock for crizotinib. The literature evidences available indicates that L1196M (the “gatekeeper” mutation) and G1269A are the two most commonly found secondary mutations in the ALK kinase domain. In a few cases, patient harbored with both mutation (Kim et al. 2013). Of note, the available evidence indicates that ALK double mutation (L1196M, G1269A) is one of the main causes for crizotinib resistance (Doebele et al. 2012; Molina et al. 2008). The prevalence of ALK double mutation (L1196M, G1269A) is also significantly higher than other mutation. These situations urge the development of new and more effective ALK inhibitors especially for the treatment of drug resistance NSCLC. For years, computational techniques in particular virtual screening (VS) have proven to be of great use to make the drug development process faster and less expensive. The available literature evidences also suggested that VS techniques proved to be efficacious in making qualitative predictions that discriminated active from inactive compounds (Oprea 2000; Chen 2008). Therefore, in the present investigation, we have employed VS technique to address the crizotinib resistance in NSCLC. We hope that this approach certainly helpful for the experimental biologist to figure out the potent candidates for NSCLC. Materials and methods Data set The three-dimensional (3D) structure of native and mutant (L1196M, G1269A) ALK structures were retrieved from the crystal structures of the Brookhaven Protein Data Bank (PDB) for the analysis (Berman et al. 2000). The corresponding PDB codes were 2XP2 and 4ANS for the native and mutant structures, respectively (Cui et al. 2011). Crizotinib was used as the small molecule for our study. The SMILES strings of the crizotinib and the lead molecules were collected from PubChem (Feldman et al. 2006) and submitted to CORINA for constructing the 3D structure of molecule (Gasteiger et al. 1990). The 3D structure of target proteins (2XP2 and 4ANS) drug molecule and lead compounds was energy-minimized using GROMACS package 4.5.3 adopting the GROMOS43a1 force field parameters before performing the computational analysis (Hess et al. 2008; Spoel et al. 2005). Virtual screening Virtual Screening (Shoichet 2004) is an important technique in computer-assisted drug discovery for screening of potential molecule from the database. This approach becomes popular in the pharmaceutical research for lead identification. Diminution of the massive virtual chemical space of small organic molecules and to screen against a specific target protein is the basic goal of the virtual screening (Tondi et al. 1999). In the present study, virtual screening technique performed with the help of PubChem database by employing crizotinib as a query (Bolton et al. 2008). It is worth stressing that PubChem database holds over 27 million records of unique chemical structures of compounds (CID) derived from nearly 70 million substance depositions (SID). The publicly available PubChem database provides great opportunities for scientists to perform VS process (Xie 2010). Several hits were obtained from the PubChem database, which were further analyzed using molecular docking studies. ADME and toxicity The bioavailability of the lead compounds was examined with the help of Lipinski’s rule of five (Lipinski et al. 1997). The molecular properties such as logP (partition coefficient), molecular weight (MW), or counts of hydrogen bond acceptors and donors in a molecule were utilized in formulating ‘‘rule of five’’ (Ertl et al. 2000). The rule states that most molecules with good membrane permeability should have molecular weight ≤500, calculated octanol–water partition coefficient, log P ≤ 5, hydrogen bond donors ≤5, acceptors ≤10 and van der Waals bumps polar surface area (PSA) <120 Å2 (Muegge 2003). In the present study, all the molecular properties for all the lead compounds were estimated by using Molinspiration program (http://www.molinspiration.com/cgi-bin/properties) (Buntrock 2002). Toxicity is the second important parameter need to be considered in the analysis of lead compounds. Infact, toxicity will account the failure of majority of the lead cases. In the present study, toxicity of the lead compound examined with the help of OSIRIS program (http://www.organic-chemistry.org/prog/peo/). The program was also helpful to evaluate the drug likeliness and drug score of the lead compounds. Nearly 5300 distinct substructure fragments created by 3300 traded drugs as well as 15,000 commercially available chemicals yielding a complete list of all available fragments with the associated drug likeliness. The drug score consolidates drug-likeliness, cLogP, logS, molecular weight, and toxicity risks. It is a total value which may be used to judge the compound’s overall potential to qualify for a drug. Molecular docking The docking study is immensely important to understand the bioactivity of the screened lead compounds. Initially, SMILES strings were used for constructing three dimensional structures of all the lead compounds. Subsequently, docking algorithm was performed with the help of Patch dock server (Schneidman et al. 2005). It is a molecular docking algorithm based on geometry. The energy minimized PDB coordinate file corresponds to the protein and the ligand molecule is the input parameters for the docking. This algorithm has three major stages (1) molecular shape representation (2) surface patch matching and (3) filtering and scoring. The Patch Dock services were available at http://bioinfo3d.cs.tau.ac.il/PatchDock/. The docked complexes were ranked based on the geometric matching score with target proteins. The geometric matching score of crizotinib with target proteins (native and mutant structures) were used as reference for filtering the lead compounds. Molecular dynamics simulation GROMACS Package 4.5.3 implemented with Gromos 43a1 force field was utilized to perform molecular dynamics (MD) of docked complexes such as native-type ALK-crizotinib complex, mutant-type ALK-crizotinib complex, native-type ALK-CID11562217 complex and mutant-type ALK-CID11562217 complex (Hess et al. 2008; Spoel et al. 2005). The protein was solvated in cubic 0.9 nm with the help of periodic boundary conditions and the SPC water model (Meagher and Carlson 2005).This resulted in the addition of 22,269 and 23,506 water molecules to the native and mutant complex structures, respectively. PRODRG server was used to generate topology of the ligand (Schuttelkopf and Van Aalten 2004). This server uses the GROMOS force field for generating topology file and assigning atom types. Six sodium (6 Na+ ions) counter ions were added to neutralize the total charge of the system and one thousand steps of steepest descent energy minimization were carried out for the proteins. After the energy minimization step, the system was equilibrated at constant temperature and pressure. Using an atom-based cutoff of 8 Å, the non bonded list was generated. Constrains bond lengths at their equilibrium values were handled by SHAKE algorithm and the long range electrostatic interactions were handled by particle-mesh Ewald algorithm (Darden et al. 1999; Van Gunsteren and Berendsen 1977). The total simulation time was set to 20,000 ps with integration time step of 2 fs. Structural analysis was done at every picosecond and trajectories were stored in traj.trr file. For instance, root mean square deviation (RMSD) was analyzed with the help of Gromacs utilities g_rms. Results and discussion Virtual screening and bioavailability analysis The present study initiated by extracting structurally similar compounds to crizotinib from the Pubchem database. The crizotinib was used was used as a query molecule. About 99 % similarity cutoff was maintained in the analysis. The results yield a total of 63 compounds. These compounds were utilized for our further study. Molinspiration program was used to predict the bioavailability of crizotinib and the lead compounds. Initially, crizotinib properties were calculated with the help of Molinspiration program (Fig. 1) and used as a control for screening the other lead compounds. The result is shown in Table 1. It is clear from the table that 3 compound such as CID: 11656144, CID: 11502981 and CID: 58659185 showed violations for the rule of five. The remaining 60 compounds have zero violations for the rule of five. This brings to the conclusion that bioavailability of these 60 compounds was significantly better in our dataset. Fig. 1 Molinspiration property explorer showing molecular properties of crizotinib Table 1 Calculations of molecular properties of crizotinib and lead compound using molinspiration S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume 1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175 2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175 3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175 4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175 5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175 6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175 7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175 8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175 9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175 10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175 11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175 12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175 13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175 14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175 15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175 16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175 17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175 18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175 19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564 20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175 21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175 22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977 23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107 24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589 25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441 26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441 27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441 28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441 29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118 30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92 31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118 32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507 33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989 34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735 35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571 36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571 37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218 38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758 39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571 40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53 41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204 42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147 43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92 44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92 45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671 46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175 47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374 48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175 49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572 50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374 51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374 52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805 53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175 54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773 55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971 56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56 57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932 58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175 59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374 60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318 61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331 62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141 63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141 64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956 Bold indicates ADME screened compounds based on Lipinsiki rule of 5 It is bare that for passing oral bioavailability criteria, number of rotatable bond should be <10 (Oprea 2000). Therefore, we have made the further refinement of these hits by restricting the number of rotatable bonds to 10. The result is presented in Table 2. It is clear from the Table 2 that almost all the 60 compounds screened from the ADME analysis possess reasonable number of rotatable bonds (<10). This result indicates that these compounds may have the potential to become a lead compound. However, toxicity is also one of the important issue could be addressed for all the lead compounds before its selection. Table 2 Details of number of rotatable bonds S. no Compound nrotb 1 Crizotinib 5 2 CID: 11597571 5 3 CID: 11626560 5 4 CID: 53234260 5 5 CID: 53234326 5 6 CID: 56671814 5 7 CID: 60197531 5 8 CID: 60197626 5 9 CID: 60198523 5 10 CID: 60198524 5 11 CID: 60198525 5 12 CID: 60199015 5 13 CID: 60199016 5 14 CID: 60199073 5 15 CID: 60199075 5 16 CID: 60199076 5 17 CID: 60199077 5 18 CID: 62705017 5 19 CID: 68625002 6 20 CID: 54613769 5 21 CID: 11662380 5 22 CID: 11626823 6 23 CID: 58659191 5 24 CID: 44560358 5 25 CID: 71239831 5 26 CID: 71239833 5 27 CID: 71240010 5 28 CID: 71240011 5 29 CID: 11496366 5 30 CID: 11562021 6 31 CID: 11626824 5 32 CID: 11598102 5 33 CID: 11641497 7 34 CID: 11690598 5 35 CID: 68563708 5 36 CID: 11562217 5 37 CID: 11612136 5 38 CID: 58659130 5 39 CID: 11625675 5 40 CID: 67084493 6 41 CID: 11676204 7 42 CID: 11684380 6 43 CID: 58659192 5 44 CID: 58659228 5 45 CID: 11503318 6 46 CID: 11510387 5 47 CID: 11568619 6 48 CID: 11575401 5 49 CID: 11647760 5 50 CID: 58659136 5 51 CID: 58659189 5 52 CID: 72986690 6 53 CID: 11676140 5 54 CID: 58659141 6 55 CID: 11705849 5 56 CID: 11719356 5 57 CID: 11647759 6 58 CID: 21110753 7 59 CID: 21110757 4 60 CID: 73386634 4 61 CID: 11647795 5 Number of rotatable bonds <10 Toxicity analysis The primary objective behind the failure of the majority of compounds in drug discovery process is the issues related to pharmacokinetics and toxicity. In the present investigation, these issues were addressed with the help of OSIRIS property explorer program. The pharmacokinetic property of a lead compound can be investigated by utilizing the parameters such as clogP and logS. The result is shown in Table 3. clogP is an entrenched measure of the compound’s hydrophilicity. The high log P values may cause poor retention because of the compound’s low hydrophilicity. It has been demonstrated that for compounds to have a reasonable probability of being well absorbed, their log P value must not be greater than 5.0. It is clear from the table that log P values of all the 60 compounds found to be in the acceptable criteria. Table 3 Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score 1 Crizotinib No No No 3.54 −5.26 3.12 0.52 2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52 3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52 4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52 5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52 6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52 7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52 8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52 9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52 10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52 11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52 12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52 13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52 14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52 15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52 16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52 17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52 18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52 19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46 20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53 21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42 22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48 23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29 24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54 25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38 26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37 27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38 28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38 29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54 30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48 31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54 32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41 33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49 34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6 35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6 36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29 37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33 38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60 39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53 40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37 41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62 42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54 43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22 44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53 45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42 46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47 47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42 48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63 49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58 50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48 51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31 52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42 53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44 54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33 55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42 56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53 57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57 58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59 59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56 60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56 61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48 Drug solubility normally affects the absorption and distribution characteristics of a compound. Infact, insufficient solubility of drug can lead to poor absorption (Lipinski et al. 1997). Our evaluated log S worth is a unit stripped logarithm (base 10) of a compound’s dissolvability measured in mol/liter. There are more than 80 % of the drugs available in the market have an (expected) log S value greater than −4. It is clear from the Table 3 that the solubility of the 60 lead compounds was found in the comparable zone with that of standard drugs to fulfill the requirements of solubility and this could be regarded as a candidate drug for oral absorption. Drug likeness The drug likeliness is imperative parameter because drug like molecules exhibit favorable absorption, distribution, metabolism, excretion, toxicological (ADMET) parameters (Tetko 2005). In this study, Osiris program was utilized to calculate the drug-likeness of crizotinib and other virtually screened compounds (Sander 2001). It is worth stressing that the drug likeness value of 60 lead compounds was found to be in acceptable criteria. Drug score and toxicity The information assessed in Table 3 shows that the 57 lead compounds should be non-mutagenic and non-tumorigenic impacts when run through the mutagenicity assessment system comparable with standard drugs used. The compounds such as CID: 11662380, CID: 58659189, CID: 58659191, and CID: 58659192 failed to pass through the Osiris program and showed mutagenic and tumorigenic effects. We have also analyzed the overall drug score (DS) for all the lead compounds and compared with that of crizotinib. The score consolidates drug- likeness, miLogP, logS, molecular weight, and toxicity risks. The DS score could also be an important parameter to judge the compound’s potential to meet all requirements to qualify for a drug. The result is demonstrated in Table 3. The reported lead compounds demonstrated moderate to good DS as compared with standard drug crizotinib. In our dataset, 17 lead compounds showed similar drug score as that of crizotinib. About five compounds such as CID: 11690598, CID: 68563708, CID: 58659130, CID: 11676204 and CID: 11575401 showed a drug score of 0.6 and above. Therefore, further examination was carried out with 57 compounds. Molecular docking Molecular docking program was employed to find out the binding affinity of lead compounds with the target protein. Docking analysis was performed twice to eliminate the false positive. The docking results are shown in Table 4. The docking score of native-type ALK-crizotinib complex was found to be 5312 and for the mutant-type ALK-crizotinib complex was found to be 4602. The lesser docking score of mutant complex clearly indicates that double mutation (L1196M and G1269A) significantly affects the binding of crizotinib with the ALK structures. It is believed that a potential lead compound is the one should have higher docking scoring than the existing drug molecule, crizotinib. Therefore, we have examined docking score for all the 57 hits both with the native type and with mutant type ALK systems. 16 hits showed higher docking score only with mutant type ALK than native type ALK and 17 more hits from our dataset showed similar dock score to that of crizotinib. Most importantly, 10 hits from our dataset showed higher score both in the native type as well as with mutant type. For instance, CID 11562217 molecule showed the highest docking score among the 10 hits in our data set. The docking score of native-type ALK-CID 11562217 complex was found to be 5662 and for the mutant-type ALK-CID 11562217 complex was found to be 5908. This result indicates that CID 11562217 has a better binding affinity not only with the native type but also with mutant ALK as compared to the crizotinib. Table 4 Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure S. no Compound ID Score 2XP2 4ANS 1 Crizotinib 5312 5226 2 CID: 11597571 5312 5226 3 CID: 11626560 5312 5226 4 CID: 53234260 5312 5226 5 CID: 53234326 5312 5226 6 CID: 56671814 5312 5226 7 CID: 60197531 5312 5226 8 CID: 60197626 5312 5226 9 CID: 60198523 5312 5226 10 CID: 60198524 5312 5226 11 CID: 60198525 5312 5226 12 CID: 60199015 5312 5226 13 CID: 60199016 5312 5226 14 CID: 60199073 5312 5226 15 CID: 60199075 5312 5226 16 CID: 60199076 5312 5226 17 CID: 60199077 5312 5226 18 CID: 62705017 5312 5226 19 CID: 68625002 5200 5342 20 CID: 54613769 5298 5308 21 CID: 11626823 5048 5226 22 CID: 44560358 5012 5386 23 CID: 71239831 5440 5776 24 CID: 71239833 5440 5776 25 CID: 71240010 5426 5504 26 CID: 71240011 5426 5504 27 CID: 11496366 5412 5420 28 CID: 11562021 5510 5492 29 CID: 11626824 5412 5420 30 CID: 11598102 5292 5294 31 CID: 11641497 5450 5138 32 CID: 11690598 4906 5138 33 CID: 68563708 4906 5138 34 CID: 11562217 5662 5908 35 CID: 11612136 5144 5032 36 CID: 58659130 5108 5294 37 CID: 11625675 4746 5052 38 CID: 67084493 4950 5334 39 CID: 11676204 4964 4962 40 CID: 11684380 4964 5424 41 CID: 59599446 5434 5704 42 CID: 11503318 5110 5138 43 CID: 11510387 5124 5372 44 CID: 11568619 5110 5138 45 CID: 11575401 4886 4826 46 CID: 11647760 5124 5372 47 CID: 58659136 5124 5372 48 CID: 72986690 5110 5138 49 CID: 11676140 4906 5484 50 CID: 58659141 5118 5278 51 CID: 11705849 5186 5370 52 CID: 11719356 5040 5238 53 CID: 11647759 5026 5118 54 CID: 21110753 5390 5526 55 CID: 21110757 4408 4604 56 CID: 73386634 4408 4604 57 CID: 11647795 5268 5212 Bold indicates the lead compounds showed higher binding score than crizotinib It is also to be noted that the pharmacokinetic and pharmacodynamic investigation of CID 11562217 indicated better results than the other lead compounds explored in our study (Fig. 2). The two dimensional structure of crizotinib was compared with CID 11562217 to get the structural attributes and the result is demonstrated in Fig. 3. It demonstrates that CID11562217 is a nitrile enhanced crizotinib. It is worth stressing that nitrile compounds with cyanide functional group could possess potential anti-tumor effects (US Patent 20060128724). The literature evidence also highlights that our lead molecule has kinase inhibiting effects. Further, the cyano-containing analogues were able to produce DNA–DNA cross-linking. The reduced DNA cross-linking was paralleled by a similar reduction in cytotoxicity indicating a relationship between cross-linking and anti-tumor effect (Jesson et al. 1987). Therefore, further validation of CID 11562217 compound was done with the help of molecular dynamics simulation study. Fig. 2 Osiris property explorer showing drug-likeliness properties of CID11562217 Fig. 3 Structure comparison between (a) crizotinib and (b) CID11562217 Molecular dynamics simulation Molecular dynamics simulation study was carried out with the help of GROMACS package 4.5.3 to explore the stability of the complex structures. In particular, the parameter, RMSD, was examined from the trajectory file and used for analyzing the complex stability. RMSD investigation can give a thought of how much the three-dimensional structure has deviated over the time. The result is shown in Fig. 4. Native type ALK-crizotinib complex structure acquired ~0.34 nm at 1000 ps during the simulations, while mutant type ALK-crizotinib complex structure acquired ~0.28 nm of backbone RMSD at 1000 ps. On the other hand, native-type ALK-CID11562217 structure acquired ~0.18 nm of backbone RMSD while mutant-type ALK-CID11562217 complex structure acquired ~0.22 nm of backbone RMSD at 1000 ps. Between a period of 2000–5000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.30 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.25 to ~0.36 nm. In the virtual complex, native-type ALK-CID11562217 structure showed a RMSD value between ~0.18 and ~0.20 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.24 nm. From the period of 5000–10,000 ps, native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.34 nm while, mutant type ALK-crizotinib complex has deviated from ~0.32 to ~0.36 nm. On the contrary, native-type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm while mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.20 to ~0.24 nm. From the beginning of 11,000 ps to the end of 15,000 ps, mutant type ALK-crizotinib complex structure showed higher deviation and attains a RMSD value of ~0.44 nm while native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.23 nm. Mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm in this simulation period. Between a period of 16,000–19,000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.35 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.43 to ~0.45 nm. For instance, native-type ALK-CID11562217 structure showed a RMSD value of ~0.25 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.22 nm. At the end of 20,000 ps the mutant type ALK-crizotinib complex structure attained RMSD of ~0.40 nm and native type ALK-crizotinib complex structure attained RMSD of ~0.35 nm. This clearly indicates that ALK double mutation disturb the structural stability and also its function. It is worth stressing that native and mutant type ALK-CID 11562217 able to maintain a RMSD of ~0.24 nm. Overall, significant difference in RMSD value observed between the crizotinib and CID 11562217 complex system. The lesser RMSD value of CID 11562217 complex demonstrates the stable binding of CID 11562217 with both native and mutant type ALK structures. Fig. 4 Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K Conclusion In the present investigation, we have addressed the crizotinib resistance in NSCLC with the help of virtual screening approach. CID 11562217 was discovered to be more drug like as it productively passed through the parameters of pharmacokinetics and toxicity. Docking study demonstrated that CID 11562217 has the highest binding affinity not only with native type ALK but also with the mutant type ALK system among the lead compounds screened from the Pubchem database. RMSD data obtained from molecular dynamic simulation revealed structural stability of the ALK-CID11562217 complex structure. It is worth stressing that our results correlate well with available experimental evidences. Of note, the available data suggests that pyrazole-substituted aminoheteroaryl compounds have potential anti-tumor effects. We hope that the findings reported here might give helpful signs to design powerful drugs against drug resistant lung cancer types. The authors express a deep sense of gratitude to the Management of Vellore Institute of Technology for all the support, assistance and constant encouragement provided by them to carry out this work. Compliance with ethical standards Conflict of interest The authors declare that they have no conflict of interest.

Document structure show

article-title	Discovery of potential ALK inhibitors by virtual screening approach
abstract	Crizotinib is an anticancer drug used for the treatment of non-small cell lung cancer. Evidences available suggest that there is a development of an acquired resistance against crizotinib action due to the emergence of several mutations in the ALK gene. It is therefore necessary to develop potent anti-cancer drugs for the treatment of crizotinib resistance non-small cell lung cancer types. In the present study, a novel class of lead molecule was identified using virtual screening, molecular docking and molecular dynamic approach. The virtual screening analysis was done using PubChem database by employing crizotinib as query and the data reduction was carried out by using molecular docking techniques. The bioavailability of the lead compounds was examined with the help of Lipinski rule of five. The screened lead molecules were analyzed for toxicity profiles, drug-likeness and other physico-chemical properties of drugs by OSIRIS program. Finally, molecular dynamics simulation was also performed to validate the binding property of the lead compound. Our analysis clearly indicates that CID 11562217, a nitrile containing compound (pyrazole-substituted aminoheteroaryl), could be the potential ALK inhibitor certainly helpful to overcome the drug resistance in non-small cell lung cancer.
p	Crizotinib is an anticancer drug used for the treatment of non-small cell lung cancer. Evidences available suggest that there is a development of an acquired resistance against crizotinib action due to the emergence of several mutations in the ALK gene. It is therefore necessary to develop potent anti-cancer drugs for the treatment of crizotinib resistance non-small cell lung cancer types. In the present study, a novel class of lead molecule was identified using virtual screening, molecular docking and molecular dynamic approach. The virtual screening analysis was done using PubChem database by employing crizotinib as query and the data reduction was carried out by using molecular docking techniques. The bioavailability of the lead compounds was examined with the help of Lipinski rule of five. The screened lead molecules were analyzed for toxicity profiles, drug-likeness and other physico-chemical properties of drugs by OSIRIS program. Finally, molecular dynamics simulation was also performed to validate the binding property of the lead compound. Our analysis clearly indicates that CID 11562217, a nitrile containing compound (pyrazole-substituted aminoheteroaryl), could be the potential ALK inhibitor certainly helpful to overcome the drug resistance in non-small cell lung cancer.
body	Introduction Lung cancer is the prominent cause of cancer deaths in the world and a global issue to be addressed (Siegel et al. 2012). Lung cancer is broadly classified into two main types based upon their histology, which are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The most common forms of NSCLC are adenocarcinoma (ADC) and squamous cell carcinoma (SCC) (Skarda et al. 2008). Chromosomal rearrangements in the anaplastic lymphoma kinase (ALK) gene that codes for anaplastic lymphoma kinase has been identified as one of the causes of NSCLC. There are two types of tyrosine kinase, receptor and cytoplasmic tyrosine kinase. The ALK is a cytoplasmic tyrosine kinase where crizotinib (a potential anticancer drug used in the treatment of NSCLC) is bound. Chromosomal rearrangements involving the ALK gene occur in different malignant conditions, including anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) (Chiarle et al. 2008). These rearrangements lead to the expression of ALK fusion genes. ALK fusion gene possesses different properties from the two genes that it was originally derived from, can then code for the new ALK fusion protein, which is abnormally and constitutively activated. The new protein contains the tyrosine kinase domain of ALK and the coiled coil domain of EML4. The coiled coil domain of EML4 allows this protein to bind with other ALK fusion proteins and form dimerised and activated fusion proteins (Katayama et al. 2012). The most prevalent ALK fusion oncogene in NSCLC is the echinoderm microtubule-associated protein-like 4 (EML4)–ALK fusion gene and is present in 4–5 % of cases of NSCLC (Young et al. 2010). An inversion in the chromosome 2 brings together the 5′ end of the EML4 gene and the 3′ end of the ALK gene resulting in the formation of the EML4-ALK fusion gene (Shaw and Solomon 2011). The affected person tend to have typical clinical features like early age of onset, little or absence of any smoking history (Shaw et al. 2009). Some of the drugs commonly used for the chemotherapeutic treatment of lung cancer are Bevacizumab, Carboplatin, Cisplatin, Crizotinib, Docetaxel, Erlotinib, Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, and Vinorelbine. Targeted drug therapy is used against NSCLC of which tyrosine kinase inhibitors are amongst the best method in treatment methodology. In particular, crizotinib is one such tyrosine kinase inhibitor which is the first drug to have gained FDA approval for the treatment of NSCLC in 2011 (Ou, 2011). Although crizotinib has proved itself as an efficient counter to ALK type NSCLC, acquired resistance has made its beneficial effects temporary and has emerged as a major roadblock for crizotinib. The literature evidences available indicates that L1196M (the “gatekeeper” mutation) and G1269A are the two most commonly found secondary mutations in the ALK kinase domain. In a few cases, patient harbored with both mutation (Kim et al. 2013). Of note, the available evidence indicates that ALK double mutation (L1196M, G1269A) is one of the main causes for crizotinib resistance (Doebele et al. 2012; Molina et al. 2008). The prevalence of ALK double mutation (L1196M, G1269A) is also significantly higher than other mutation. These situations urge the development of new and more effective ALK inhibitors especially for the treatment of drug resistance NSCLC. For years, computational techniques in particular virtual screening (VS) have proven to be of great use to make the drug development process faster and less expensive. The available literature evidences also suggested that VS techniques proved to be efficacious in making qualitative predictions that discriminated active from inactive compounds (Oprea 2000; Chen 2008). Therefore, in the present investigation, we have employed VS technique to address the crizotinib resistance in NSCLC. We hope that this approach certainly helpful for the experimental biologist to figure out the potent candidates for NSCLC. Materials and methods Data set The three-dimensional (3D) structure of native and mutant (L1196M, G1269A) ALK structures were retrieved from the crystal structures of the Brookhaven Protein Data Bank (PDB) for the analysis (Berman et al. 2000). The corresponding PDB codes were 2XP2 and 4ANS for the native and mutant structures, respectively (Cui et al. 2011). Crizotinib was used as the small molecule for our study. The SMILES strings of the crizotinib and the lead molecules were collected from PubChem (Feldman et al. 2006) and submitted to CORINA for constructing the 3D structure of molecule (Gasteiger et al. 1990). The 3D structure of target proteins (2XP2 and 4ANS) drug molecule and lead compounds was energy-minimized using GROMACS package 4.5.3 adopting the GROMOS43a1 force field parameters before performing the computational analysis (Hess et al. 2008; Spoel et al. 2005). Virtual screening Virtual Screening (Shoichet 2004) is an important technique in computer-assisted drug discovery for screening of potential molecule from the database. This approach becomes popular in the pharmaceutical research for lead identification. Diminution of the massive virtual chemical space of small organic molecules and to screen against a specific target protein is the basic goal of the virtual screening (Tondi et al. 1999). In the present study, virtual screening technique performed with the help of PubChem database by employing crizotinib as a query (Bolton et al. 2008). It is worth stressing that PubChem database holds over 27 million records of unique chemical structures of compounds (CID) derived from nearly 70 million substance depositions (SID). The publicly available PubChem database provides great opportunities for scientists to perform VS process (Xie 2010). Several hits were obtained from the PubChem database, which were further analyzed using molecular docking studies. ADME and toxicity The bioavailability of the lead compounds was examined with the help of Lipinski’s rule of five (Lipinski et al. 1997). The molecular properties such as logP (partition coefficient), molecular weight (MW), or counts of hydrogen bond acceptors and donors in a molecule were utilized in formulating ‘‘rule of five’’ (Ertl et al. 2000). The rule states that most molecules with good membrane permeability should have molecular weight ≤500, calculated octanol–water partition coefficient, log P ≤ 5, hydrogen bond donors ≤5, acceptors ≤10 and van der Waals bumps polar surface area (PSA) <120 Å2 (Muegge 2003). In the present study, all the molecular properties for all the lead compounds were estimated by using Molinspiration program (http://www.molinspiration.com/cgi-bin/properties) (Buntrock 2002). Toxicity is the second important parameter need to be considered in the analysis of lead compounds. Infact, toxicity will account the failure of majority of the lead cases. In the present study, toxicity of the lead compound examined with the help of OSIRIS program (http://www.organic-chemistry.org/prog/peo/). The program was also helpful to evaluate the drug likeliness and drug score of the lead compounds. Nearly 5300 distinct substructure fragments created by 3300 traded drugs as well as 15,000 commercially available chemicals yielding a complete list of all available fragments with the associated drug likeliness. The drug score consolidates drug-likeliness, cLogP, logS, molecular weight, and toxicity risks. It is a total value which may be used to judge the compound’s overall potential to qualify for a drug. Molecular docking The docking study is immensely important to understand the bioactivity of the screened lead compounds. Initially, SMILES strings were used for constructing three dimensional structures of all the lead compounds. Subsequently, docking algorithm was performed with the help of Patch dock server (Schneidman et al. 2005). It is a molecular docking algorithm based on geometry. The energy minimized PDB coordinate file corresponds to the protein and the ligand molecule is the input parameters for the docking. This algorithm has three major stages (1) molecular shape representation (2) surface patch matching and (3) filtering and scoring. The Patch Dock services were available at http://bioinfo3d.cs.tau.ac.il/PatchDock/. The docked complexes were ranked based on the geometric matching score with target proteins. The geometric matching score of crizotinib with target proteins (native and mutant structures) were used as reference for filtering the lead compounds. Molecular dynamics simulation GROMACS Package 4.5.3 implemented with Gromos 43a1 force field was utilized to perform molecular dynamics (MD) of docked complexes such as native-type ALK-crizotinib complex, mutant-type ALK-crizotinib complex, native-type ALK-CID11562217 complex and mutant-type ALK-CID11562217 complex (Hess et al. 2008; Spoel et al. 2005). The protein was solvated in cubic 0.9 nm with the help of periodic boundary conditions and the SPC water model (Meagher and Carlson 2005).This resulted in the addition of 22,269 and 23,506 water molecules to the native and mutant complex structures, respectively. PRODRG server was used to generate topology of the ligand (Schuttelkopf and Van Aalten 2004). This server uses the GROMOS force field for generating topology file and assigning atom types. Six sodium (6 Na+ ions) counter ions were added to neutralize the total charge of the system and one thousand steps of steepest descent energy minimization were carried out for the proteins. After the energy minimization step, the system was equilibrated at constant temperature and pressure. Using an atom-based cutoff of 8 Å, the non bonded list was generated. Constrains bond lengths at their equilibrium values were handled by SHAKE algorithm and the long range electrostatic interactions were handled by particle-mesh Ewald algorithm (Darden et al. 1999; Van Gunsteren and Berendsen 1977). The total simulation time was set to 20,000 ps with integration time step of 2 fs. Structural analysis was done at every picosecond and trajectories were stored in traj.trr file. For instance, root mean square deviation (RMSD) was analyzed with the help of Gromacs utilities g_rms. Results and discussion Virtual screening and bioavailability analysis The present study initiated by extracting structurally similar compounds to crizotinib from the Pubchem database. The crizotinib was used was used as a query molecule. About 99 % similarity cutoff was maintained in the analysis. The results yield a total of 63 compounds. These compounds were utilized for our further study. Molinspiration program was used to predict the bioavailability of crizotinib and the lead compounds. Initially, crizotinib properties were calculated with the help of Molinspiration program (Fig. 1) and used as a control for screening the other lead compounds. The result is shown in Table 1. It is clear from the table that 3 compound such as CID: 11656144, CID: 11502981 and CID: 58659185 showed violations for the rule of five. The remaining 60 compounds have zero violations for the rule of five. This brings to the conclusion that bioavailability of these 60 compounds was significantly better in our dataset. Fig. 1 Molinspiration property explorer showing molecular properties of crizotinib Table 1 Calculations of molecular properties of crizotinib and lead compound using molinspiration S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume 1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175 2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175 3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175 4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175 5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175 6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175 7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175 8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175 9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175 10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175 11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175 12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175 13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175 14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175 15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175 16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175 17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175 18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175 19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564 20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175 21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175 22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977 23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107 24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589 25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441 26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441 27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441 28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441 29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118 30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92 31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118 32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507 33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989 34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735 35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571 36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571 37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218 38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758 39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571 40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53 41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204 42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147 43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92 44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92 45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671 46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175 47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374 48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175 49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572 50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374 51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374 52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805 53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175 54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773 55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971 56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56 57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932 58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175 59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374 60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318 61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331 62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141 63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141 64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956 Bold indicates ADME screened compounds based on Lipinsiki rule of 5 It is bare that for passing oral bioavailability criteria, number of rotatable bond should be <10 (Oprea 2000). Therefore, we have made the further refinement of these hits by restricting the number of rotatable bonds to 10. The result is presented in Table 2. It is clear from the Table 2 that almost all the 60 compounds screened from the ADME analysis possess reasonable number of rotatable bonds (<10). This result indicates that these compounds may have the potential to become a lead compound. However, toxicity is also one of the important issue could be addressed for all the lead compounds before its selection. Table 2 Details of number of rotatable bonds S. no Compound nrotb 1 Crizotinib 5 2 CID: 11597571 5 3 CID: 11626560 5 4 CID: 53234260 5 5 CID: 53234326 5 6 CID: 56671814 5 7 CID: 60197531 5 8 CID: 60197626 5 9 CID: 60198523 5 10 CID: 60198524 5 11 CID: 60198525 5 12 CID: 60199015 5 13 CID: 60199016 5 14 CID: 60199073 5 15 CID: 60199075 5 16 CID: 60199076 5 17 CID: 60199077 5 18 CID: 62705017 5 19 CID: 68625002 6 20 CID: 54613769 5 21 CID: 11662380 5 22 CID: 11626823 6 23 CID: 58659191 5 24 CID: 44560358 5 25 CID: 71239831 5 26 CID: 71239833 5 27 CID: 71240010 5 28 CID: 71240011 5 29 CID: 11496366 5 30 CID: 11562021 6 31 CID: 11626824 5 32 CID: 11598102 5 33 CID: 11641497 7 34 CID: 11690598 5 35 CID: 68563708 5 36 CID: 11562217 5 37 CID: 11612136 5 38 CID: 58659130 5 39 CID: 11625675 5 40 CID: 67084493 6 41 CID: 11676204 7 42 CID: 11684380 6 43 CID: 58659192 5 44 CID: 58659228 5 45 CID: 11503318 6 46 CID: 11510387 5 47 CID: 11568619 6 48 CID: 11575401 5 49 CID: 11647760 5 50 CID: 58659136 5 51 CID: 58659189 5 52 CID: 72986690 6 53 CID: 11676140 5 54 CID: 58659141 6 55 CID: 11705849 5 56 CID: 11719356 5 57 CID: 11647759 6 58 CID: 21110753 7 59 CID: 21110757 4 60 CID: 73386634 4 61 CID: 11647795 5 Number of rotatable bonds <10 Toxicity analysis The primary objective behind the failure of the majority of compounds in drug discovery process is the issues related to pharmacokinetics and toxicity. In the present investigation, these issues were addressed with the help of OSIRIS property explorer program. The pharmacokinetic property of a lead compound can be investigated by utilizing the parameters such as clogP and logS. The result is shown in Table 3. clogP is an entrenched measure of the compound’s hydrophilicity. The high log P values may cause poor retention because of the compound’s low hydrophilicity. It has been demonstrated that for compounds to have a reasonable probability of being well absorbed, their log P value must not be greater than 5.0. It is clear from the table that log P values of all the 60 compounds found to be in the acceptable criteria. Table 3 Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score 1 Crizotinib No No No 3.54 −5.26 3.12 0.52 2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52 3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52 4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52 5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52 6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52 7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52 8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52 9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52 10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52 11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52 12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52 13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52 14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52 15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52 16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52 17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52 18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52 19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46 20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53 21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42 22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48 23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29 24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54 25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38 26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37 27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38 28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38 29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54 30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48 31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54 32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41 33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49 34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6 35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6 36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29 37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33 38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60 39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53 40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37 41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62 42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54 43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22 44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53 45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42 46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47 47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42 48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63 49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58 50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48 51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31 52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42 53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44 54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33 55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42 56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53 57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57 58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59 59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56 60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56 61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48 Drug solubility normally affects the absorption and distribution characteristics of a compound. Infact, insufficient solubility of drug can lead to poor absorption (Lipinski et al. 1997). Our evaluated log S worth is a unit stripped logarithm (base 10) of a compound’s dissolvability measured in mol/liter. There are more than 80 % of the drugs available in the market have an (expected) log S value greater than −4. It is clear from the Table 3 that the solubility of the 60 lead compounds was found in the comparable zone with that of standard drugs to fulfill the requirements of solubility and this could be regarded as a candidate drug for oral absorption. Drug likeness The drug likeliness is imperative parameter because drug like molecules exhibit favorable absorption, distribution, metabolism, excretion, toxicological (ADMET) parameters (Tetko 2005). In this study, Osiris program was utilized to calculate the drug-likeness of crizotinib and other virtually screened compounds (Sander 2001). It is worth stressing that the drug likeness value of 60 lead compounds was found to be in acceptable criteria. Drug score and toxicity The information assessed in Table 3 shows that the 57 lead compounds should be non-mutagenic and non-tumorigenic impacts when run through the mutagenicity assessment system comparable with standard drugs used. The compounds such as CID: 11662380, CID: 58659189, CID: 58659191, and CID: 58659192 failed to pass through the Osiris program and showed mutagenic and tumorigenic effects. We have also analyzed the overall drug score (DS) for all the lead compounds and compared with that of crizotinib. The score consolidates drug- likeness, miLogP, logS, molecular weight, and toxicity risks. The DS score could also be an important parameter to judge the compound’s potential to meet all requirements to qualify for a drug. The result is demonstrated in Table 3. The reported lead compounds demonstrated moderate to good DS as compared with standard drug crizotinib. In our dataset, 17 lead compounds showed similar drug score as that of crizotinib. About five compounds such as CID: 11690598, CID: 68563708, CID: 58659130, CID: 11676204 and CID: 11575401 showed a drug score of 0.6 and above. Therefore, further examination was carried out with 57 compounds. Molecular docking Molecular docking program was employed to find out the binding affinity of lead compounds with the target protein. Docking analysis was performed twice to eliminate the false positive. The docking results are shown in Table 4. The docking score of native-type ALK-crizotinib complex was found to be 5312 and for the mutant-type ALK-crizotinib complex was found to be 4602. The lesser docking score of mutant complex clearly indicates that double mutation (L1196M and G1269A) significantly affects the binding of crizotinib with the ALK structures. It is believed that a potential lead compound is the one should have higher docking scoring than the existing drug molecule, crizotinib. Therefore, we have examined docking score for all the 57 hits both with the native type and with mutant type ALK systems. 16 hits showed higher docking score only with mutant type ALK than native type ALK and 17 more hits from our dataset showed similar dock score to that of crizotinib. Most importantly, 10 hits from our dataset showed higher score both in the native type as well as with mutant type. For instance, CID 11562217 molecule showed the highest docking score among the 10 hits in our data set. The docking score of native-type ALK-CID 11562217 complex was found to be 5662 and for the mutant-type ALK-CID 11562217 complex was found to be 5908. This result indicates that CID 11562217 has a better binding affinity not only with the native type but also with mutant ALK as compared to the crizotinib. Table 4 Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure S. no Compound ID Score 2XP2 4ANS 1 Crizotinib 5312 5226 2 CID: 11597571 5312 5226 3 CID: 11626560 5312 5226 4 CID: 53234260 5312 5226 5 CID: 53234326 5312 5226 6 CID: 56671814 5312 5226 7 CID: 60197531 5312 5226 8 CID: 60197626 5312 5226 9 CID: 60198523 5312 5226 10 CID: 60198524 5312 5226 11 CID: 60198525 5312 5226 12 CID: 60199015 5312 5226 13 CID: 60199016 5312 5226 14 CID: 60199073 5312 5226 15 CID: 60199075 5312 5226 16 CID: 60199076 5312 5226 17 CID: 60199077 5312 5226 18 CID: 62705017 5312 5226 19 CID: 68625002 5200 5342 20 CID: 54613769 5298 5308 21 CID: 11626823 5048 5226 22 CID: 44560358 5012 5386 23 CID: 71239831 5440 5776 24 CID: 71239833 5440 5776 25 CID: 71240010 5426 5504 26 CID: 71240011 5426 5504 27 CID: 11496366 5412 5420 28 CID: 11562021 5510 5492 29 CID: 11626824 5412 5420 30 CID: 11598102 5292 5294 31 CID: 11641497 5450 5138 32 CID: 11690598 4906 5138 33 CID: 68563708 4906 5138 34 CID: 11562217 5662 5908 35 CID: 11612136 5144 5032 36 CID: 58659130 5108 5294 37 CID: 11625675 4746 5052 38 CID: 67084493 4950 5334 39 CID: 11676204 4964 4962 40 CID: 11684380 4964 5424 41 CID: 59599446 5434 5704 42 CID: 11503318 5110 5138 43 CID: 11510387 5124 5372 44 CID: 11568619 5110 5138 45 CID: 11575401 4886 4826 46 CID: 11647760 5124 5372 47 CID: 58659136 5124 5372 48 CID: 72986690 5110 5138 49 CID: 11676140 4906 5484 50 CID: 58659141 5118 5278 51 CID: 11705849 5186 5370 52 CID: 11719356 5040 5238 53 CID: 11647759 5026 5118 54 CID: 21110753 5390 5526 55 CID: 21110757 4408 4604 56 CID: 73386634 4408 4604 57 CID: 11647795 5268 5212 Bold indicates the lead compounds showed higher binding score than crizotinib It is also to be noted that the pharmacokinetic and pharmacodynamic investigation of CID 11562217 indicated better results than the other lead compounds explored in our study (Fig. 2). The two dimensional structure of crizotinib was compared with CID 11562217 to get the structural attributes and the result is demonstrated in Fig. 3. It demonstrates that CID11562217 is a nitrile enhanced crizotinib. It is worth stressing that nitrile compounds with cyanide functional group could possess potential anti-tumor effects (US Patent 20060128724). The literature evidence also highlights that our lead molecule has kinase inhibiting effects. Further, the cyano-containing analogues were able to produce DNA–DNA cross-linking. The reduced DNA cross-linking was paralleled by a similar reduction in cytotoxicity indicating a relationship between cross-linking and anti-tumor effect (Jesson et al. 1987). Therefore, further validation of CID 11562217 compound was done with the help of molecular dynamics simulation study. Fig. 2 Osiris property explorer showing drug-likeliness properties of CID11562217 Fig. 3 Structure comparison between (a) crizotinib and (b) CID11562217 Molecular dynamics simulation Molecular dynamics simulation study was carried out with the help of GROMACS package 4.5.3 to explore the stability of the complex structures. In particular, the parameter, RMSD, was examined from the trajectory file and used for analyzing the complex stability. RMSD investigation can give a thought of how much the three-dimensional structure has deviated over the time. The result is shown in Fig. 4. Native type ALK-crizotinib complex structure acquired ~0.34 nm at 1000 ps during the simulations, while mutant type ALK-crizotinib complex structure acquired ~0.28 nm of backbone RMSD at 1000 ps. On the other hand, native-type ALK-CID11562217 structure acquired ~0.18 nm of backbone RMSD while mutant-type ALK-CID11562217 complex structure acquired ~0.22 nm of backbone RMSD at 1000 ps. Between a period of 2000–5000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.30 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.25 to ~0.36 nm. In the virtual complex, native-type ALK-CID11562217 structure showed a RMSD value between ~0.18 and ~0.20 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.24 nm. From the period of 5000–10,000 ps, native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.34 nm while, mutant type ALK-crizotinib complex has deviated from ~0.32 to ~0.36 nm. On the contrary, native-type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm while mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.20 to ~0.24 nm. From the beginning of 11,000 ps to the end of 15,000 ps, mutant type ALK-crizotinib complex structure showed higher deviation and attains a RMSD value of ~0.44 nm while native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.23 nm. Mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm in this simulation period. Between a period of 16,000–19,000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.35 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.43 to ~0.45 nm. For instance, native-type ALK-CID11562217 structure showed a RMSD value of ~0.25 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.22 nm. At the end of 20,000 ps the mutant type ALK-crizotinib complex structure attained RMSD of ~0.40 nm and native type ALK-crizotinib complex structure attained RMSD of ~0.35 nm. This clearly indicates that ALK double mutation disturb the structural stability and also its function. It is worth stressing that native and mutant type ALK-CID 11562217 able to maintain a RMSD of ~0.24 nm. Overall, significant difference in RMSD value observed between the crizotinib and CID 11562217 complex system. The lesser RMSD value of CID 11562217 complex demonstrates the stable binding of CID 11562217 with both native and mutant type ALK structures. Fig. 4 Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K Conclusion In the present investigation, we have addressed the crizotinib resistance in NSCLC with the help of virtual screening approach. CID 11562217 was discovered to be more drug like as it productively passed through the parameters of pharmacokinetics and toxicity. Docking study demonstrated that CID 11562217 has the highest binding affinity not only with native type ALK but also with the mutant type ALK system among the lead compounds screened from the Pubchem database. RMSD data obtained from molecular dynamic simulation revealed structural stability of the ALK-CID11562217 complex structure. It is worth stressing that our results correlate well with available experimental evidences. Of note, the available data suggests that pyrazole-substituted aminoheteroaryl compounds have potential anti-tumor effects. We hope that the findings reported here might give helpful signs to design powerful drugs against drug resistant lung cancer types.
sec	Introduction Lung cancer is the prominent cause of cancer deaths in the world and a global issue to be addressed (Siegel et al. 2012). Lung cancer is broadly classified into two main types based upon their histology, which are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The most common forms of NSCLC are adenocarcinoma (ADC) and squamous cell carcinoma (SCC) (Skarda et al. 2008). Chromosomal rearrangements in the anaplastic lymphoma kinase (ALK) gene that codes for anaplastic lymphoma kinase has been identified as one of the causes of NSCLC. There are two types of tyrosine kinase, receptor and cytoplasmic tyrosine kinase. The ALK is a cytoplasmic tyrosine kinase where crizotinib (a potential anticancer drug used in the treatment of NSCLC) is bound. Chromosomal rearrangements involving the ALK gene occur in different malignant conditions, including anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) (Chiarle et al. 2008). These rearrangements lead to the expression of ALK fusion genes. ALK fusion gene possesses different properties from the two genes that it was originally derived from, can then code for the new ALK fusion protein, which is abnormally and constitutively activated. The new protein contains the tyrosine kinase domain of ALK and the coiled coil domain of EML4. The coiled coil domain of EML4 allows this protein to bind with other ALK fusion proteins and form dimerised and activated fusion proteins (Katayama et al. 2012). The most prevalent ALK fusion oncogene in NSCLC is the echinoderm microtubule-associated protein-like 4 (EML4)–ALK fusion gene and is present in 4–5 % of cases of NSCLC (Young et al. 2010). An inversion in the chromosome 2 brings together the 5′ end of the EML4 gene and the 3′ end of the ALK gene resulting in the formation of the EML4-ALK fusion gene (Shaw and Solomon 2011). The affected person tend to have typical clinical features like early age of onset, little or absence of any smoking history (Shaw et al. 2009). Some of the drugs commonly used for the chemotherapeutic treatment of lung cancer are Bevacizumab, Carboplatin, Cisplatin, Crizotinib, Docetaxel, Erlotinib, Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, and Vinorelbine. Targeted drug therapy is used against NSCLC of which tyrosine kinase inhibitors are amongst the best method in treatment methodology. In particular, crizotinib is one such tyrosine kinase inhibitor which is the first drug to have gained FDA approval for the treatment of NSCLC in 2011 (Ou, 2011). Although crizotinib has proved itself as an efficient counter to ALK type NSCLC, acquired resistance has made its beneficial effects temporary and has emerged as a major roadblock for crizotinib. The literature evidences available indicates that L1196M (the “gatekeeper” mutation) and G1269A are the two most commonly found secondary mutations in the ALK kinase domain. In a few cases, patient harbored with both mutation (Kim et al. 2013). Of note, the available evidence indicates that ALK double mutation (L1196M, G1269A) is one of the main causes for crizotinib resistance (Doebele et al. 2012; Molina et al. 2008). The prevalence of ALK double mutation (L1196M, G1269A) is also significantly higher than other mutation. These situations urge the development of new and more effective ALK inhibitors especially for the treatment of drug resistance NSCLC. For years, computational techniques in particular virtual screening (VS) have proven to be of great use to make the drug development process faster and less expensive. The available literature evidences also suggested that VS techniques proved to be efficacious in making qualitative predictions that discriminated active from inactive compounds (Oprea 2000; Chen 2008). Therefore, in the present investigation, we have employed VS technique to address the crizotinib resistance in NSCLC. We hope that this approach certainly helpful for the experimental biologist to figure out the potent candidates for NSCLC.
title	Introduction
p	Lung cancer is the prominent cause of cancer deaths in the world and a global issue to be addressed (Siegel et al. 2012). Lung cancer is broadly classified into two main types based upon their histology, which are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The most common forms of NSCLC are adenocarcinoma (ADC) and squamous cell carcinoma (SCC) (Skarda et al. 2008). Chromosomal rearrangements in the anaplastic lymphoma kinase (ALK) gene that codes for anaplastic lymphoma kinase has been identified as one of the causes of NSCLC. There are two types of tyrosine kinase, receptor and cytoplasmic tyrosine kinase. The ALK is a cytoplasmic tyrosine kinase where crizotinib (a potential anticancer drug used in the treatment of NSCLC) is bound. Chromosomal rearrangements involving the ALK gene occur in different malignant conditions, including anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) (Chiarle et al. 2008). These rearrangements lead to the expression of ALK fusion genes. ALK fusion gene possesses different properties from the two genes that it was originally derived from, can then code for the new ALK fusion protein, which is abnormally and constitutively activated. The new protein contains the tyrosine kinase domain of ALK and the coiled coil domain of EML4. The coiled coil domain of EML4 allows this protein to bind with other ALK fusion proteins and form dimerised and activated fusion proteins (Katayama et al. 2012). The most prevalent ALK fusion oncogene in NSCLC is the echinoderm microtubule-associated protein-like 4 (EML4)–ALK fusion gene and is present in 4–5 % of cases of NSCLC (Young et al. 2010). An inversion in the chromosome 2 brings together the 5′ end of the EML4 gene and the 3′ end of the ALK gene resulting in the formation of the EML4-ALK fusion gene (Shaw and Solomon 2011). The affected person tend to have typical clinical features like early age of onset, little or absence of any smoking history (Shaw et al. 2009). Some of the drugs commonly used for the chemotherapeutic treatment of lung cancer are Bevacizumab, Carboplatin, Cisplatin, Crizotinib, Docetaxel, Erlotinib, Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, and Vinorelbine. Targeted drug therapy is used against NSCLC of which tyrosine kinase inhibitors are amongst the best method in treatment methodology. In particular, crizotinib is one such tyrosine kinase inhibitor which is the first drug to have gained FDA approval for the treatment of NSCLC in 2011 (Ou, 2011). Although crizotinib has proved itself as an efficient counter to ALK type NSCLC, acquired resistance has made its beneficial effects temporary and has emerged as a major roadblock for crizotinib. The literature evidences available indicates that L1196M (the “gatekeeper” mutation) and G1269A are the two most commonly found secondary mutations in the ALK kinase domain. In a few cases, patient harbored with both mutation (Kim et al. 2013). Of note, the available evidence indicates that ALK double mutation (L1196M, G1269A) is one of the main causes for crizotinib resistance (Doebele et al. 2012; Molina et al. 2008). The prevalence of ALK double mutation (L1196M, G1269A) is also significantly higher than other mutation. These situations urge the development of new and more effective ALK inhibitors especially for the treatment of drug resistance NSCLC. For years, computational techniques in particular virtual screening (VS) have proven to be of great use to make the drug development process faster and less expensive. The available literature evidences also suggested that VS techniques proved to be efficacious in making qualitative predictions that discriminated active from inactive compounds (Oprea 2000; Chen 2008). Therefore, in the present investigation, we have employed VS technique to address the crizotinib resistance in NSCLC. We hope that this approach certainly helpful for the experimental biologist to figure out the potent candidates for NSCLC.
sec	Materials and methods Data set The three-dimensional (3D) structure of native and mutant (L1196M, G1269A) ALK structures were retrieved from the crystal structures of the Brookhaven Protein Data Bank (PDB) for the analysis (Berman et al. 2000). The corresponding PDB codes were 2XP2 and 4ANS for the native and mutant structures, respectively (Cui et al. 2011). Crizotinib was used as the small molecule for our study. The SMILES strings of the crizotinib and the lead molecules were collected from PubChem (Feldman et al. 2006) and submitted to CORINA for constructing the 3D structure of molecule (Gasteiger et al. 1990). The 3D structure of target proteins (2XP2 and 4ANS) drug molecule and lead compounds was energy-minimized using GROMACS package 4.5.3 adopting the GROMOS43a1 force field parameters before performing the computational analysis (Hess et al. 2008; Spoel et al. 2005). Virtual screening Virtual Screening (Shoichet 2004) is an important technique in computer-assisted drug discovery for screening of potential molecule from the database. This approach becomes popular in the pharmaceutical research for lead identification. Diminution of the massive virtual chemical space of small organic molecules and to screen against a specific target protein is the basic goal of the virtual screening (Tondi et al. 1999). In the present study, virtual screening technique performed with the help of PubChem database by employing crizotinib as a query (Bolton et al. 2008). It is worth stressing that PubChem database holds over 27 million records of unique chemical structures of compounds (CID) derived from nearly 70 million substance depositions (SID). The publicly available PubChem database provides great opportunities for scientists to perform VS process (Xie 2010). Several hits were obtained from the PubChem database, which were further analyzed using molecular docking studies. ADME and toxicity The bioavailability of the lead compounds was examined with the help of Lipinski’s rule of five (Lipinski et al. 1997). The molecular properties such as logP (partition coefficient), molecular weight (MW), or counts of hydrogen bond acceptors and donors in a molecule were utilized in formulating ‘‘rule of five’’ (Ertl et al. 2000). The rule states that most molecules with good membrane permeability should have molecular weight ≤500, calculated octanol–water partition coefficient, log P ≤ 5, hydrogen bond donors ≤5, acceptors ≤10 and van der Waals bumps polar surface area (PSA) <120 Å2 (Muegge 2003). In the present study, all the molecular properties for all the lead compounds were estimated by using Molinspiration program (http://www.molinspiration.com/cgi-bin/properties) (Buntrock 2002). Toxicity is the second important parameter need to be considered in the analysis of lead compounds. Infact, toxicity will account the failure of majority of the lead cases. In the present study, toxicity of the lead compound examined with the help of OSIRIS program (http://www.organic-chemistry.org/prog/peo/). The program was also helpful to evaluate the drug likeliness and drug score of the lead compounds. Nearly 5300 distinct substructure fragments created by 3300 traded drugs as well as 15,000 commercially available chemicals yielding a complete list of all available fragments with the associated drug likeliness. The drug score consolidates drug-likeliness, cLogP, logS, molecular weight, and toxicity risks. It is a total value which may be used to judge the compound’s overall potential to qualify for a drug. Molecular docking The docking study is immensely important to understand the bioactivity of the screened lead compounds. Initially, SMILES strings were used for constructing three dimensional structures of all the lead compounds. Subsequently, docking algorithm was performed with the help of Patch dock server (Schneidman et al. 2005). It is a molecular docking algorithm based on geometry. The energy minimized PDB coordinate file corresponds to the protein and the ligand molecule is the input parameters for the docking. This algorithm has three major stages (1) molecular shape representation (2) surface patch matching and (3) filtering and scoring. The Patch Dock services were available at http://bioinfo3d.cs.tau.ac.il/PatchDock/. The docked complexes were ranked based on the geometric matching score with target proteins. The geometric matching score of crizotinib with target proteins (native and mutant structures) were used as reference for filtering the lead compounds. Molecular dynamics simulation GROMACS Package 4.5.3 implemented with Gromos 43a1 force field was utilized to perform molecular dynamics (MD) of docked complexes such as native-type ALK-crizotinib complex, mutant-type ALK-crizotinib complex, native-type ALK-CID11562217 complex and mutant-type ALK-CID11562217 complex (Hess et al. 2008; Spoel et al. 2005). The protein was solvated in cubic 0.9 nm with the help of periodic boundary conditions and the SPC water model (Meagher and Carlson 2005).This resulted in the addition of 22,269 and 23,506 water molecules to the native and mutant complex structures, respectively. PRODRG server was used to generate topology of the ligand (Schuttelkopf and Van Aalten 2004). This server uses the GROMOS force field for generating topology file and assigning atom types. Six sodium (6 Na+ ions) counter ions were added to neutralize the total charge of the system and one thousand steps of steepest descent energy minimization were carried out for the proteins. After the energy minimization step, the system was equilibrated at constant temperature and pressure. Using an atom-based cutoff of 8 Å, the non bonded list was generated. Constrains bond lengths at their equilibrium values were handled by SHAKE algorithm and the long range electrostatic interactions were handled by particle-mesh Ewald algorithm (Darden et al. 1999; Van Gunsteren and Berendsen 1977). The total simulation time was set to 20,000 ps with integration time step of 2 fs. Structural analysis was done at every picosecond and trajectories were stored in traj.trr file. For instance, root mean square deviation (RMSD) was analyzed with the help of Gromacs utilities g_rms.
title	Materials and methods
sec	Data set The three-dimensional (3D) structure of native and mutant (L1196M, G1269A) ALK structures were retrieved from the crystal structures of the Brookhaven Protein Data Bank (PDB) for the analysis (Berman et al. 2000). The corresponding PDB codes were 2XP2 and 4ANS for the native and mutant structures, respectively (Cui et al. 2011). Crizotinib was used as the small molecule for our study. The SMILES strings of the crizotinib and the lead molecules were collected from PubChem (Feldman et al. 2006) and submitted to CORINA for constructing the 3D structure of molecule (Gasteiger et al. 1990). The 3D structure of target proteins (2XP2 and 4ANS) drug molecule and lead compounds was energy-minimized using GROMACS package 4.5.3 adopting the GROMOS43a1 force field parameters before performing the computational analysis (Hess et al. 2008; Spoel et al. 2005).
title	Data set
p	The three-dimensional (3D) structure of native and mutant (L1196M, G1269A) ALK structures were retrieved from the crystal structures of the Brookhaven Protein Data Bank (PDB) for the analysis (Berman et al. 2000). The corresponding PDB codes were 2XP2 and 4ANS for the native and mutant structures, respectively (Cui et al. 2011). Crizotinib was used as the small molecule for our study. The SMILES strings of the crizotinib and the lead molecules were collected from PubChem (Feldman et al. 2006) and submitted to CORINA for constructing the 3D structure of molecule (Gasteiger et al. 1990). The 3D structure of target proteins (2XP2 and 4ANS) drug molecule and lead compounds was energy-minimized using GROMACS package 4.5.3 adopting the GROMOS43a1 force field parameters before performing the computational analysis (Hess et al. 2008; Spoel et al. 2005).
sec	Virtual screening Virtual Screening (Shoichet 2004) is an important technique in computer-assisted drug discovery for screening of potential molecule from the database. This approach becomes popular in the pharmaceutical research for lead identification. Diminution of the massive virtual chemical space of small organic molecules and to screen against a specific target protein is the basic goal of the virtual screening (Tondi et al. 1999). In the present study, virtual screening technique performed with the help of PubChem database by employing crizotinib as a query (Bolton et al. 2008). It is worth stressing that PubChem database holds over 27 million records of unique chemical structures of compounds (CID) derived from nearly 70 million substance depositions (SID). The publicly available PubChem database provides great opportunities for scientists to perform VS process (Xie 2010). Several hits were obtained from the PubChem database, which were further analyzed using molecular docking studies.
title	Virtual screening
p	Virtual Screening (Shoichet 2004) is an important technique in computer-assisted drug discovery for screening of potential molecule from the database. This approach becomes popular in the pharmaceutical research for lead identification. Diminution of the massive virtual chemical space of small organic molecules and to screen against a specific target protein is the basic goal of the virtual screening (Tondi et al. 1999). In the present study,
p	virtual screening technique performed with the help of PubChem database by employing crizotinib as a query (Bolton et al. 2008). It is worth stressing that PubChem database holds over 27 million records of unique chemical structures of compounds (CID) derived from nearly 70 million substance depositions (SID). The publicly available PubChem database provides great opportunities for scientists to perform VS process (Xie 2010). Several hits were obtained from the PubChem database, which were further analyzed using molecular docking studies.
sec	ADME and toxicity The bioavailability of the lead compounds was examined with the help of Lipinski’s rule of five (Lipinski et al. 1997). The molecular properties such as logP (partition coefficient), molecular weight (MW), or counts of hydrogen bond acceptors and donors in a molecule were utilized in formulating ‘‘rule of five’’ (Ertl et al. 2000). The rule states that most molecules with good membrane permeability should have molecular weight ≤500, calculated octanol–water partition coefficient, log P ≤ 5, hydrogen bond donors ≤5, acceptors ≤10 and van der Waals bumps polar surface area (PSA) <120 Å2 (Muegge 2003). In the present study, all the molecular properties for all the lead compounds were estimated by using Molinspiration program (http://www.molinspiration.com/cgi-bin/properties) (Buntrock 2002). Toxicity is the second important parameter need to be considered in the analysis of lead compounds. Infact, toxicity will account the failure of majority of the lead cases. In the present study, toxicity of the lead compound examined with the help of OSIRIS program (http://www.organic-chemistry.org/prog/peo/). The program was also helpful to evaluate the drug likeliness and drug score of the lead compounds. Nearly 5300 distinct substructure fragments created by 3300 traded drugs as well as 15,000 commercially available chemicals yielding a complete list of all available fragments with the associated drug likeliness. The drug score consolidates drug-likeliness, cLogP, logS, molecular weight, and toxicity risks. It is a total value which may be used to judge the compound’s overall potential to qualify for a drug.
title	ADME and toxicity
p	The bioavailability of the lead compounds was examined with the help of Lipinski’s rule of five (Lipinski et al. 1997). The molecular properties such as logP (partition coefficient), molecular weight (MW), or counts of hydrogen bond acceptors and donors in a molecule were utilized in formulating ‘‘rule of five’’ (Ertl et al. 2000). The rule states that most molecules with good membrane permeability should have molecular weight ≤500, calculated octanol–water partition coefficient, log P ≤ 5, hydrogen bond donors ≤5, acceptors ≤10 and van der Waals bumps polar surface area (PSA) <120 Å2 (Muegge 2003). In the present study, all the molecular properties for all the lead compounds were estimated by using Molinspiration program (http://www.molinspiration.com/cgi-bin/properties) (Buntrock 2002). Toxicity is the second important parameter need to be considered in the analysis of lead compounds. Infact, toxicity will account the failure of majority of the lead cases. In the present study, toxicity of the lead compound examined with the help of OSIRIS program (http://www.organic-chemistry.org/prog/peo/). The program was also helpful to evaluate the drug likeliness and drug score of the lead compounds. Nearly 5300 distinct substructure fragments created by 3300 traded drugs as well as 15,000 commercially available chemicals yielding a complete list of all available fragments with the associated drug likeliness. The drug score consolidates drug-likeliness, cLogP, logS, molecular weight, and toxicity risks. It is a total value which may be used to judge the compound’s overall potential to qualify for a drug.
sec	Molecular docking The docking study is immensely important to understand the bioactivity of the screened lead compounds. Initially, SMILES strings were used for constructing three dimensional structures of all the lead compounds. Subsequently, docking algorithm was performed with the help of Patch dock server (Schneidman et al. 2005). It is a molecular docking algorithm based on geometry. The energy minimized PDB coordinate file corresponds to the protein and the ligand molecule is the input parameters for the docking. This algorithm has three major stages (1) molecular shape representation (2) surface patch matching and (3) filtering and scoring. The Patch Dock services were available at http://bioinfo3d.cs.tau.ac.il/PatchDock/. The docked complexes were ranked based on the geometric matching score with target proteins. The geometric matching score of crizotinib with target proteins (native and mutant structures) were used as reference for filtering the lead compounds.
title	Molecular docking
p	The docking study is immensely important to understand the bioactivity of the screened lead compounds. Initially, SMILES strings were used for constructing three dimensional structures of all the lead compounds. Subsequently, docking algorithm was performed with the help of Patch dock server (Schneidman et al. 2005). It is a molecular docking algorithm based on geometry. The energy minimized PDB coordinate file corresponds to the protein and the ligand molecule is the input parameters for the docking. This algorithm has three major stages (1) molecular shape representation (2) surface patch matching and (3) filtering and scoring. The Patch Dock services were available at http://bioinfo3d.cs.tau.ac.il/PatchDock/. The docked complexes were ranked based on the geometric matching score with target proteins. The geometric matching score of crizotinib with target proteins (native and mutant structures) were used as reference for filtering the lead compounds.
sec	Molecular dynamics simulation GROMACS Package 4.5.3 implemented with Gromos 43a1 force field was utilized to perform molecular dynamics (MD) of docked complexes such as native-type ALK-crizotinib complex, mutant-type ALK-crizotinib complex, native-type ALK-CID11562217 complex and mutant-type ALK-CID11562217 complex (Hess et al. 2008; Spoel et al. 2005). The protein was solvated in cubic 0.9 nm with the help of periodic boundary conditions and the SPC water model (Meagher and Carlson 2005).This resulted in the addition of 22,269 and 23,506 water molecules to the native and mutant complex structures, respectively. PRODRG server was used to generate topology of the ligand (Schuttelkopf and Van Aalten 2004). This server uses the GROMOS force field for generating topology file and assigning atom types. Six sodium (6 Na+ ions) counter ions were added to neutralize the total charge of the system and one thousand steps of steepest descent energy minimization were carried out for the proteins. After the energy minimization step, the system was equilibrated at constant temperature and pressure. Using an atom-based cutoff of 8 Å, the non bonded list was generated. Constrains bond lengths at their equilibrium values were handled by SHAKE algorithm and the long range electrostatic interactions were handled by particle-mesh Ewald algorithm (Darden et al. 1999; Van Gunsteren and Berendsen 1977). The total simulation time was set to 20,000 ps with integration time step of 2 fs. Structural analysis was done at every picosecond and trajectories were stored in traj.trr file. For instance, root mean square deviation (RMSD) was analyzed with the help of Gromacs utilities g_rms.
title	Molecular dynamics simulation
p	GROMACS Package 4.5.3 implemented with Gromos 43a1 force field was utilized to perform molecular dynamics (MD) of docked complexes such as native-type ALK-crizotinib complex, mutant-type ALK-crizotinib complex, native-type ALK-CID11562217 complex and mutant-type ALK-CID11562217 complex (Hess et al. 2008; Spoel et al. 2005). The protein was solvated in cubic 0.9 nm with the help of periodic boundary conditions and the SPC water model (Meagher and Carlson 2005).This resulted in the addition of 22,269 and 23,506 water molecules to the native and mutant complex structures, respectively. PRODRG server was used to generate topology of the ligand (Schuttelkopf and Van Aalten 2004). This server uses the GROMOS force field for generating topology file and assigning atom types. Six sodium (6 Na+ ions) counter ions were added to neutralize the total charge of the system and one thousand steps of steepest descent energy minimization were carried out for the proteins. After the energy minimization step, the system was equilibrated at constant temperature and pressure. Using an atom-based cutoff of 8 Å, the non bonded list was generated. Constrains bond lengths at their equilibrium values were handled by SHAKE algorithm and the long range electrostatic interactions were handled by particle-mesh Ewald algorithm (Darden et al. 1999; Van Gunsteren and Berendsen 1977). The total simulation time was set to 20,000 ps with integration time step of 2 fs. Structural analysis was done at every picosecond and trajectories were stored in traj.trr file. For instance, root mean square deviation (RMSD) was analyzed with the help of Gromacs utilities g_rms.
sec	Results and discussion Virtual screening and bioavailability analysis The present study initiated by extracting structurally similar compounds to crizotinib from the Pubchem database. The crizotinib was used was used as a query molecule. About 99 % similarity cutoff was maintained in the analysis. The results yield a total of 63 compounds. These compounds were utilized for our further study. Molinspiration program was used to predict the bioavailability of crizotinib and the lead compounds. Initially, crizotinib properties were calculated with the help of Molinspiration program (Fig. 1) and used as a control for screening the other lead compounds. The result is shown in Table 1. It is clear from the table that 3 compound such as CID: 11656144, CID: 11502981 and CID: 58659185 showed violations for the rule of five. The remaining 60 compounds have zero violations for the rule of five. This brings to the conclusion that bioavailability of these 60 compounds was significantly better in our dataset. Fig. 1 Molinspiration property explorer showing molecular properties of crizotinib Table 1 Calculations of molecular properties of crizotinib and lead compound using molinspiration S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume 1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175 2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175 3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175 4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175 5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175 6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175 7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175 8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175 9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175 10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175 11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175 12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175 13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175 14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175 15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175 16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175 17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175 18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175 19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564 20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175 21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175 22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977 23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107 24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589 25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441 26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441 27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441 28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441 29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118 30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92 31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118 32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507 33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989 34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735 35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571 36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571 37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218 38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758 39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571 40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53 41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204 42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147 43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92 44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92 45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671 46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175 47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374 48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175 49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572 50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374 51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374 52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805 53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175 54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773 55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971 56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56 57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932 58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175 59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374 60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318 61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331 62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141 63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141 64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956 Bold indicates ADME screened compounds based on Lipinsiki rule of 5 It is bare that for passing oral bioavailability criteria, number of rotatable bond should be <10 (Oprea 2000). Therefore, we have made the further refinement of these hits by restricting the number of rotatable bonds to 10. The result is presented in Table 2. It is clear from the Table 2 that almost all the 60 compounds screened from the ADME analysis possess reasonable number of rotatable bonds (<10). This result indicates that these compounds may have the potential to become a lead compound. However, toxicity is also one of the important issue could be addressed for all the lead compounds before its selection. Table 2 Details of number of rotatable bonds S. no Compound nrotb 1 Crizotinib 5 2 CID: 11597571 5 3 CID: 11626560 5 4 CID: 53234260 5 5 CID: 53234326 5 6 CID: 56671814 5 7 CID: 60197531 5 8 CID: 60197626 5 9 CID: 60198523 5 10 CID: 60198524 5 11 CID: 60198525 5 12 CID: 60199015 5 13 CID: 60199016 5 14 CID: 60199073 5 15 CID: 60199075 5 16 CID: 60199076 5 17 CID: 60199077 5 18 CID: 62705017 5 19 CID: 68625002 6 20 CID: 54613769 5 21 CID: 11662380 5 22 CID: 11626823 6 23 CID: 58659191 5 24 CID: 44560358 5 25 CID: 71239831 5 26 CID: 71239833 5 27 CID: 71240010 5 28 CID: 71240011 5 29 CID: 11496366 5 30 CID: 11562021 6 31 CID: 11626824 5 32 CID: 11598102 5 33 CID: 11641497 7 34 CID: 11690598 5 35 CID: 68563708 5 36 CID: 11562217 5 37 CID: 11612136 5 38 CID: 58659130 5 39 CID: 11625675 5 40 CID: 67084493 6 41 CID: 11676204 7 42 CID: 11684380 6 43 CID: 58659192 5 44 CID: 58659228 5 45 CID: 11503318 6 46 CID: 11510387 5 47 CID: 11568619 6 48 CID: 11575401 5 49 CID: 11647760 5 50 CID: 58659136 5 51 CID: 58659189 5 52 CID: 72986690 6 53 CID: 11676140 5 54 CID: 58659141 6 55 CID: 11705849 5 56 CID: 11719356 5 57 CID: 11647759 6 58 CID: 21110753 7 59 CID: 21110757 4 60 CID: 73386634 4 61 CID: 11647795 5 Number of rotatable bonds <10 Toxicity analysis The primary objective behind the failure of the majority of compounds in drug discovery process is the issues related to pharmacokinetics and toxicity. In the present investigation, these issues were addressed with the help of OSIRIS property explorer program. The pharmacokinetic property of a lead compound can be investigated by utilizing the parameters such as clogP and logS. The result is shown in Table 3. clogP is an entrenched measure of the compound’s hydrophilicity. The high log P values may cause poor retention because of the compound’s low hydrophilicity. It has been demonstrated that for compounds to have a reasonable probability of being well absorbed, their log P value must not be greater than 5.0. It is clear from the table that log P values of all the 60 compounds found to be in the acceptable criteria. Table 3 Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score 1 Crizotinib No No No 3.54 −5.26 3.12 0.52 2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52 3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52 4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52 5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52 6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52 7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52 8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52 9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52 10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52 11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52 12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52 13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52 14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52 15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52 16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52 17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52 18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52 19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46 20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53 21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42 22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48 23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29 24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54 25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38 26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37 27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38 28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38 29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54 30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48 31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54 32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41 33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49 34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6 35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6 36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29 37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33 38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60 39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53 40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37 41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62 42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54 43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22 44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53 45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42 46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47 47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42 48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63 49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58 50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48 51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31 52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42 53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44 54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33 55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42 56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53 57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57 58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59 59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56 60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56 61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48 Drug solubility normally affects the absorption and distribution characteristics of a compound. Infact, insufficient solubility of drug can lead to poor absorption (Lipinski et al. 1997). Our evaluated log S worth is a unit stripped logarithm (base 10) of a compound’s dissolvability measured in mol/liter. There are more than 80 % of the drugs available in the market have an (expected) log S value greater than −4. It is clear from the Table 3 that the solubility of the 60 lead compounds was found in the comparable zone with that of standard drugs to fulfill the requirements of solubility and this could be regarded as a candidate drug for oral absorption. Drug likeness The drug likeliness is imperative parameter because drug like molecules exhibit favorable absorption, distribution, metabolism, excretion, toxicological (ADMET) parameters (Tetko 2005). In this study, Osiris program was utilized to calculate the drug-likeness of crizotinib and other virtually screened compounds (Sander 2001). It is worth stressing that the drug likeness value of 60 lead compounds was found to be in acceptable criteria. Drug score and toxicity The information assessed in Table 3 shows that the 57 lead compounds should be non-mutagenic and non-tumorigenic impacts when run through the mutagenicity assessment system comparable with standard drugs used. The compounds such as CID: 11662380, CID: 58659189, CID: 58659191, and CID: 58659192 failed to pass through the Osiris program and showed mutagenic and tumorigenic effects. We have also analyzed the overall drug score (DS) for all the lead compounds and compared with that of crizotinib. The score consolidates drug- likeness, miLogP, logS, molecular weight, and toxicity risks. The DS score could also be an important parameter to judge the compound’s potential to meet all requirements to qualify for a drug. The result is demonstrated in Table 3. The reported lead compounds demonstrated moderate to good DS as compared with standard drug crizotinib. In our dataset, 17 lead compounds showed similar drug score as that of crizotinib. About five compounds such as CID: 11690598, CID: 68563708, CID: 58659130, CID: 11676204 and CID: 11575401 showed a drug score of 0.6 and above. Therefore, further examination was carried out with 57 compounds. Molecular docking Molecular docking program was employed to find out the binding affinity of lead compounds with the target protein. Docking analysis was performed twice to eliminate the false positive. The docking results are shown in Table 4. The docking score of native-type ALK-crizotinib complex was found to be 5312 and for the mutant-type ALK-crizotinib complex was found to be 4602. The lesser docking score of mutant complex clearly indicates that double mutation (L1196M and G1269A) significantly affects the binding of crizotinib with the ALK structures. It is believed that a potential lead compound is the one should have higher docking scoring than the existing drug molecule, crizotinib. Therefore, we have examined docking score for all the 57 hits both with the native type and with mutant type ALK systems. 16 hits showed higher docking score only with mutant type ALK than native type ALK and 17 more hits from our dataset showed similar dock score to that of crizotinib. Most importantly, 10 hits from our dataset showed higher score both in the native type as well as with mutant type. For instance, CID 11562217 molecule showed the highest docking score among the 10 hits in our data set. The docking score of native-type ALK-CID 11562217 complex was found to be 5662 and for the mutant-type ALK-CID 11562217 complex was found to be 5908. This result indicates that CID 11562217 has a better binding affinity not only with the native type but also with mutant ALK as compared to the crizotinib. Table 4 Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure S. no Compound ID Score 2XP2 4ANS 1 Crizotinib 5312 5226 2 CID: 11597571 5312 5226 3 CID: 11626560 5312 5226 4 CID: 53234260 5312 5226 5 CID: 53234326 5312 5226 6 CID: 56671814 5312 5226 7 CID: 60197531 5312 5226 8 CID: 60197626 5312 5226 9 CID: 60198523 5312 5226 10 CID: 60198524 5312 5226 11 CID: 60198525 5312 5226 12 CID: 60199015 5312 5226 13 CID: 60199016 5312 5226 14 CID: 60199073 5312 5226 15 CID: 60199075 5312 5226 16 CID: 60199076 5312 5226 17 CID: 60199077 5312 5226 18 CID: 62705017 5312 5226 19 CID: 68625002 5200 5342 20 CID: 54613769 5298 5308 21 CID: 11626823 5048 5226 22 CID: 44560358 5012 5386 23 CID: 71239831 5440 5776 24 CID: 71239833 5440 5776 25 CID: 71240010 5426 5504 26 CID: 71240011 5426 5504 27 CID: 11496366 5412 5420 28 CID: 11562021 5510 5492 29 CID: 11626824 5412 5420 30 CID: 11598102 5292 5294 31 CID: 11641497 5450 5138 32 CID: 11690598 4906 5138 33 CID: 68563708 4906 5138 34 CID: 11562217 5662 5908 35 CID: 11612136 5144 5032 36 CID: 58659130 5108 5294 37 CID: 11625675 4746 5052 38 CID: 67084493 4950 5334 39 CID: 11676204 4964 4962 40 CID: 11684380 4964 5424 41 CID: 59599446 5434 5704 42 CID: 11503318 5110 5138 43 CID: 11510387 5124 5372 44 CID: 11568619 5110 5138 45 CID: 11575401 4886 4826 46 CID: 11647760 5124 5372 47 CID: 58659136 5124 5372 48 CID: 72986690 5110 5138 49 CID: 11676140 4906 5484 50 CID: 58659141 5118 5278 51 CID: 11705849 5186 5370 52 CID: 11719356 5040 5238 53 CID: 11647759 5026 5118 54 CID: 21110753 5390 5526 55 CID: 21110757 4408 4604 56 CID: 73386634 4408 4604 57 CID: 11647795 5268 5212 Bold indicates the lead compounds showed higher binding score than crizotinib It is also to be noted that the pharmacokinetic and pharmacodynamic investigation of CID 11562217 indicated better results than the other lead compounds explored in our study (Fig. 2). The two dimensional structure of crizotinib was compared with CID 11562217 to get the structural attributes and the result is demonstrated in Fig. 3. It demonstrates that CID11562217 is a nitrile enhanced crizotinib. It is worth stressing that nitrile compounds with cyanide functional group could possess potential anti-tumor effects (US Patent 20060128724). The literature evidence also highlights that our lead molecule has kinase inhibiting effects. Further, the cyano-containing analogues were able to produce DNA–DNA cross-linking. The reduced DNA cross-linking was paralleled by a similar reduction in cytotoxicity indicating a relationship between cross-linking and anti-tumor effect (Jesson et al. 1987). Therefore, further validation of CID 11562217 compound was done with the help of molecular dynamics simulation study. Fig. 2 Osiris property explorer showing drug-likeliness properties of CID11562217 Fig. 3 Structure comparison between (a) crizotinib and (b) CID11562217 Molecular dynamics simulation Molecular dynamics simulation study was carried out with the help of GROMACS package 4.5.3 to explore the stability of the complex structures. In particular, the parameter, RMSD, was examined from the trajectory file and used for analyzing the complex stability. RMSD investigation can give a thought of how much the three-dimensional structure has deviated over the time. The result is shown in Fig. 4. Native type ALK-crizotinib complex structure acquired ~0.34 nm at 1000 ps during the simulations, while mutant type ALK-crizotinib complex structure acquired ~0.28 nm of backbone RMSD at 1000 ps. On the other hand, native-type ALK-CID11562217 structure acquired ~0.18 nm of backbone RMSD while mutant-type ALK-CID11562217 complex structure acquired ~0.22 nm of backbone RMSD at 1000 ps. Between a period of 2000–5000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.30 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.25 to ~0.36 nm. In the virtual complex, native-type ALK-CID11562217 structure showed a RMSD value between ~0.18 and ~0.20 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.24 nm. From the period of 5000–10,000 ps, native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.34 nm while, mutant type ALK-crizotinib complex has deviated from ~0.32 to ~0.36 nm. On the contrary, native-type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm while mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.20 to ~0.24 nm. From the beginning of 11,000 ps to the end of 15,000 ps, mutant type ALK-crizotinib complex structure showed higher deviation and attains a RMSD value of ~0.44 nm while native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.23 nm. Mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm in this simulation period. Between a period of 16,000–19,000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.35 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.43 to ~0.45 nm. For instance, native-type ALK-CID11562217 structure showed a RMSD value of ~0.25 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.22 nm. At the end of 20,000 ps the mutant type ALK-crizotinib complex structure attained RMSD of ~0.40 nm and native type ALK-crizotinib complex structure attained RMSD of ~0.35 nm. This clearly indicates that ALK double mutation disturb the structural stability and also its function. It is worth stressing that native and mutant type ALK-CID 11562217 able to maintain a RMSD of ~0.24 nm. Overall, significant difference in RMSD value observed between the crizotinib and CID 11562217 complex system. The lesser RMSD value of CID 11562217 complex demonstrates the stable binding of CID 11562217 with both native and mutant type ALK structures. Fig. 4 Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K
title	Results and discussion
sec	Virtual screening and bioavailability analysis The present study initiated by extracting structurally similar compounds to crizotinib from the Pubchem database. The crizotinib was used was used as a query molecule. About 99 % similarity cutoff was maintained in the analysis. The results yield a total of 63 compounds. These compounds were utilized for our further study. Molinspiration program was used to predict the bioavailability of crizotinib and the lead compounds. Initially, crizotinib properties were calculated with the help of Molinspiration program (Fig. 1) and used as a control for screening the other lead compounds. The result is shown in Table 1. It is clear from the table that 3 compound such as CID: 11656144, CID: 11502981 and CID: 58659185 showed violations for the rule of five. The remaining 60 compounds have zero violations for the rule of five. This brings to the conclusion that bioavailability of these 60 compounds was significantly better in our dataset. Fig. 1 Molinspiration property explorer showing molecular properties of crizotinib Table 1 Calculations of molecular properties of crizotinib and lead compound using molinspiration S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume 1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175 2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175 3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175 4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175 5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175 6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175 7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175 8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175 9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175 10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175 11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175 12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175 13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175 14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175 15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175 16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175 17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175 18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175 19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564 20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175 21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175 22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977 23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107 24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589 25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441 26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441 27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441 28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441 29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118 30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92 31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118 32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507 33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989 34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735 35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571 36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571 37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218 38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758 39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571 40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53 41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204 42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147 43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92 44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92 45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671 46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175 47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374 48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175 49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572 50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374 51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374 52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805 53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175 54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773 55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971 56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56 57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932 58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175 59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374 60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318 61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331 62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141 63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141 64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956 Bold indicates ADME screened compounds based on Lipinsiki rule of 5 It is bare that for passing oral bioavailability criteria, number of rotatable bond should be <10 (Oprea 2000). Therefore, we have made the further refinement of these hits by restricting the number of rotatable bonds to 10. The result is presented in Table 2. It is clear from the Table 2 that almost all the 60 compounds screened from the ADME analysis possess reasonable number of rotatable bonds (<10). This result indicates that these compounds may have the potential to become a lead compound. However, toxicity is also one of the important issue could be addressed for all the lead compounds before its selection. Table 2 Details of number of rotatable bonds S. no Compound nrotb 1 Crizotinib 5 2 CID: 11597571 5 3 CID: 11626560 5 4 CID: 53234260 5 5 CID: 53234326 5 6 CID: 56671814 5 7 CID: 60197531 5 8 CID: 60197626 5 9 CID: 60198523 5 10 CID: 60198524 5 11 CID: 60198525 5 12 CID: 60199015 5 13 CID: 60199016 5 14 CID: 60199073 5 15 CID: 60199075 5 16 CID: 60199076 5 17 CID: 60199077 5 18 CID: 62705017 5 19 CID: 68625002 6 20 CID: 54613769 5 21 CID: 11662380 5 22 CID: 11626823 6 23 CID: 58659191 5 24 CID: 44560358 5 25 CID: 71239831 5 26 CID: 71239833 5 27 CID: 71240010 5 28 CID: 71240011 5 29 CID: 11496366 5 30 CID: 11562021 6 31 CID: 11626824 5 32 CID: 11598102 5 33 CID: 11641497 7 34 CID: 11690598 5 35 CID: 68563708 5 36 CID: 11562217 5 37 CID: 11612136 5 38 CID: 58659130 5 39 CID: 11625675 5 40 CID: 67084493 6 41 CID: 11676204 7 42 CID: 11684380 6 43 CID: 58659192 5 44 CID: 58659228 5 45 CID: 11503318 6 46 CID: 11510387 5 47 CID: 11568619 6 48 CID: 11575401 5 49 CID: 11647760 5 50 CID: 58659136 5 51 CID: 58659189 5 52 CID: 72986690 6 53 CID: 11676140 5 54 CID: 58659141 6 55 CID: 11705849 5 56 CID: 11719356 5 57 CID: 11647759 6 58 CID: 21110753 7 59 CID: 21110757 4 60 CID: 73386634 4 61 CID: 11647795 5 Number of rotatable bonds <10
title	Virtual screening and bioavailability analysis
p	The present study initiated by extracting structurally similar compounds to crizotinib from the Pubchem database. The crizotinib was used was used as a query molecule. About 99 % similarity cutoff was maintained in the analysis. The results yield a total of 63 compounds. These compounds were utilized for our further study. Molinspiration program was used to predict the bioavailability of crizotinib and the lead compounds. Initially, crizotinib properties were calculated with the help of Molinspiration program (Fig. 1) and used as a control for screening the other lead compounds. The result is shown in Table 1. It is clear from the table that 3 compound such as CID: 11656144, CID: 11502981 and CID: 58659185 showed violations for the rule of five. The remaining 60 compounds have zero violations for the rule of five. This brings to the conclusion that bioavailability of these 60 compounds was significantly better in our dataset. Fig. 1 Molinspiration property explorer showing molecular properties of crizotinib Table 1 Calculations of molecular properties of crizotinib and lead compound using molinspiration S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume 1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175 2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175 3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175 4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175 5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175 6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175 7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175 8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175 9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175 10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175 11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175 12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175 13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175 14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175 15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175 16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175 17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175 18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175 19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564 20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175 21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175 22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977 23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107 24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589 25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441 26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441 27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441 28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441 29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118 30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92 31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118 32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507 33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989 34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735 35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571 36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571 37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218 38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758 39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571 40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53 41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204 42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147 43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92 44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92 45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671 46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175 47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374 48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175 49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572 50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374 51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374 52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805 53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175 54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773 55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971 56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56 57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932 58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175 59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374 60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318 61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331 62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141 63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141 64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956 Bold indicates ADME screened compounds based on Lipinsiki rule of 5
figure	Fig. 1 Molinspiration property explorer showing molecular properties of crizotinib
label	Fig. 1
caption	Molinspiration property explorer showing molecular properties of crizotinib
p	Molinspiration property explorer showing molecular properties of crizotinib
table-wrap	Table 1 Calculations of molecular properties of crizotinib and lead compound using molinspiration S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume 1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175 2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175 3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175 4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175 5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175 6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175 7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175 8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175 9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175 10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175 11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175 12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175 13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175 14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175 15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175 16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175 17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175 18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175 19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564 20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175 21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175 22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977 23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107 24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589 25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441 26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441 27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441 28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441 29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118 30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92 31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118 32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507 33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989 34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735 35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571 36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571 37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218 38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758 39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571 40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53 41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204 42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147 43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92 44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92 45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671 46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175 47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374 48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175 49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572 50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374 51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374 52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805 53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175 54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773 55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971 56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56 57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932 58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175 59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374 60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318 61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331 62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141 63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141 64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956 Bold indicates ADME screened compounds based on Lipinsiki rule of 5
label	Table 1
caption	Calculations of molecular properties of crizotinib and lead compound using molinspiration
p	Calculations of molecular properties of crizotinib and lead compound using molinspiration
table	S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume 1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175 2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175 3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175 4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175 5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175 6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175 7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175 8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175 9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175 10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175 11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175 12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175 13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175 14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175 15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175 16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175 17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175 18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175 19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564 20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175 21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175 22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977 23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107 24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589 25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441 26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441 27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441 28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441 29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118 30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92 31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118 32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507 33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989 34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735 35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571 36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571 37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218 38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758 39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571 40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53 41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204 42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147 43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92 44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92 45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671 46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175 47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374 48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175 49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572 50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374 51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374 52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805 53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175 54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773 55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971 56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56 57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932 58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175 59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374 60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318 61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331 62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141 63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141 64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956
tr	S. no Compound miLogP TPSA MW nON nOHNH nviolations Volume
th	S. no
th	Compound
th	miLogP
th	TPSA
th	MW
th	nON
th	nOHNH
th	nviolations
th	Volume
tr	1 Crizotinib 4.006 78.002 450.345 6 3 0 375.175
td	1
td	Crizotinib
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	2 CID:11597571 4.006 78.002 450.345 6 3 0 375.175
td	2
td	CID:11597571
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	3 CID: 11626560 4.006 78.002 450.345 6 3 0 375.175
td	3
td	CID: 11626560
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	4 CID: 53234260 4.006 78.002 450.345 6 3 0 375.175
td	4
td	CID: 53234260
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	5 CID: 53234326 4.006 78.002 450.345 6 3 0 375.175
td	5
td	CID: 53234326
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	6 CID: 56671814 4.006 78.002 450.345 6 3 0 375.175
td	6
td	CID: 56671814
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	7 CID: 60197531 4.006 78.002 450.345 6 3 0 375.175
td	7
td	CID: 60197531
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	8 CID: 60197626 4.006 78.002 450.345 6 3 0 375.175
td	8
td	CID: 60197626
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	9 CID: 60198523 4.006 78.002 450.345 6 3 0 375.175
td	9
td	CID: 60198523
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	10 CID: 60198524 4.006 78.002 450.345 6 3 0 375.175
td	10
td	CID: 60198524
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	11 CID: 60198525 4.006 78.002 450.345 6 3 0 375.175
td	11
td	CID: 60198525
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	12 CID: 60199015 4.006 78.002 450.345 6 3 0 375.175
td	12
td	CID: 60199015
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	13 CID: 60199016 4.006 78.002 450.345 6 3 0 375.175
td	13
td	CID: 60199016
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	14 CID: 60199073 4.006 78.002 450.345 6 3 0 375.175
td	14
td	CID: 60199073
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	15 CID: 60199075 4.006 78.002 450.345 6 3 0 375.175
td	15
td	CID: 60199075
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	16 CID: 60199076 4.006 78.002 450.345 6 3 0 375.175
td	16
td	CID: 60199076
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	17 CID: 60199077 4.006 78.002 450.345 6 3 0 375.175
td	17
td	CID: 60199077
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	18 CID: 62705017 4.006 78.002 450.345 6 3 0 375.175
td	18
td	CID: 62705017
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	19 CID: 68625002 4.752 78.002 478.399 6 3 0 408.564
td	19
td	CID: 68625002
td	4.752
td	78.002
td	478.399
td	6
td	3
td	0
td	408.564
tr	20 CID: 54613769 4.006 78.002 450.345 6 3 0 375.175
td	20
td	CID: 54613769
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	21 CID: 11662380 4.006 78.002 450.345 6 3 0 375.175
td	21
td	CID: 11662380
td	4.006
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	22 CID: 11626823 4.389 78.002 464.372 6 3 0 391.977
td	22
td	CID: 11626823
td	4.389
td	78.002
td	464.372
td	6
td	3
td	0
td	391.977
tr	23 CID: 58659191 4.098 78.002 468.335 6 3 0 380.107
td	23
td	CID: 58659191
td	4.098
td	78.002
td	468.335
td	6
td	3
td	0
td	380.107
tr	24 CID: 44560358 3.643 78.002 436.318 6 3 0 358.589
td	24
td	CID: 44560358
td	3.643
td	78.002
td	436.318
td	6
td	3
td	0
td	358.589
tr	25 CID: 71239831 4.479 78.002 490.41 6 3 0 414.441
td	25
td	CID: 71239831
td	4.479
td	78.002
td	490.41
td	6
td	3
td	0
td	414.441
tr	26 CID: 71239833 4.479 78.002 490.41 6 3 0 414.441
td	26
td	CID: 71239833
td	4.479
td	78.002
td	490.41
td	6
td	3
td	0
td	414.441
tr	27 CID: 71240010 4.479 78.002 490.41 6 3 0 414.441
td	27
td	CID: 71240010
td	4.479
td	78.002
td	490.41
td	6
td	3
td	0
td	414.441
tr	28 CID: 71240011 4.479 78.002 490.41 6 3 0 414.441
td	28
td	CID: 71240011
td	4.479
td	78.002
td	490.41
td	6
td	3
td	0
td	414.441
tr	29 CID: 11496366 4.602 69.213 464.372 6 2 0 392.118
td	29
td	CID: 11496366
td	4.602
td	69.213
td	464.372
td	6
td	2
td	0
td	392.118
tr	30 CID: 11562021 4.978 69.213 478.399 6 2 0 408.92
td	30
td	CID: 11562021
td	4.978
td	69.213
td	478.399
td	6
td	2
td	0
td	408.92
tr	31 CID: 11626824 4.602 69.213 464.372 6 2 0 392.118
td	31
td	CID: 11626824
td	4.602
td	69.213
td	464.372
td	6
td	2
td	0
td	392.118
tr	32 CID: 11656144 5.275 69.213 492.426 6 2 1 425.507
td	32
td	CID: 11656144
td	5.275
td	69.213
td	492.426
td	6
td	2
td	1
td	425.507
tr	33 CID: 11598102 4.734 78.002 476.383 6 3 0 397.989
td	33
td	CID: 11598102
td	4.734
td	78.002
td	476.383
td	6
td	3
td	0
td	397.989
tr	34 CID: 11641497 3.508 81.24 479.387 7 3 0 404.735
td	34
td	CID: 11641497
td	3.508
td	81.24
td	479.387
td	7
td	3
td	0
td	404.735
tr	35 CID: 11690598 3.492 78.002 433.89 6 3 0 366.571
td	35
td	CID: 11690598
td	3.492
td	78.002
td	433.89
td	6
td	3
td	0
td	366.571
tr	36 CID: 68563708 3.492 78.002 433.89 6 3 0 366.571
td	36
td	CID: 68563708
td	3.492
td	78.002
td	433.89
td	6
td	3
td	0
td	366.571
tr	37 CID: 11562217 4.387 93.005 489.382 7 2 0 409.218
td	37
td	CID: 11562217
td	4.387
td	93.005
td	489.382
td	7
td	2
td	0
td	409.218
tr	38 CID: 11612136 4.556 75.209 451.329 6 2 0 371.758
td	38
td	CID: 11612136
td	4.556
td	75.209
td	451.329
td	6
td	2
td	0
td	371.758
tr	39 CID: 58659130 3.492 78.002 433.89 6 3 0 366.571
td	39
td	CID: 58659130
td	3.492
td	78.002
td	433.89
td	6
td	3
td	0
td	366.571
tr	40 CID: 11625675 4.921 65.975 409.292 5 2 0 339.53
td	40
td	CID: 11625675
td	4.921
td	65.975
td	409.292
td	5
td	2
td	0
td	339.53
tr	41 CID: 67084493 4.58 78.002 476.383 6 3 0 398.204
td	41
td	CID: 67084493
td	4.58
td	78.002
td	476.383
td	6
td	3
td	0
td	398.204
tr	42 CID: 11676204 3.967 78.002 424.307 6 3 0 352.147
td	42
td	CID: 11676204
td	3.967
td	78.002
td	424.307
td	6
td	3
td	0
td	352.147
tr	43 CID: 11684380 4.985 69.213 478.399 6 2 0 408.92
td	43
td	CID: 11684380
td	4.985
td	69.213
td	478.399
td	6
td	2
td	0
td	408.92
tr	44 CID: 58659192 4.825 78.002 494.373 6 3 0 402.92
td	44
td	CID: 58659192
td	4.825
td	78.002
td	494.373
td	6
td	3
td	0
td	402.92
tr	45 CID: 59599446 3.445 98.230 480.371 7 4 0 399.671
td	45
td	CID: 59599446
td	3.445
td	98.230
td	480.371
td	7
td	4
td	0
td	399.671
tr	46 CID: 11503318 4.357 78.002 450.345 6 3 0 375.175
td	46
td	CID: 11503318
td	4.357
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	47 CID: 11510387 4.086 78.002 436.318 6 3 0 358.374
td	47
td	CID: 11510387
td	4.086
td	78.002
td	436.318
td	6
td	3
td	0
td	358.374
tr	48 CID: 11568619 4.357 78.002 450.345 6 3 0 375.175
td	48
td	CID: 11568619
td	4.357
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	49 CID: 11575401 3.816 78.002 422.291 6 3 0 341.572
td	49
td	CID: 11575401
td	3.816
td	78.002
td	422.291
td	6
td	3
td	0
td	341.572
tr	50 CID: 11647760 4.086 78.002 436.318 6 3 0 358.374
td	50
td	CID: 11647760
td	4.086
td	78.002
td	436.318
td	6
td	3
td	0
td	358.374
tr	51 CID: 58659136 4.086 78.002 436.318 6 3 0 358.374
td	51
td	CID: 58659136
td	4.086
td	78.002
td	436.318
td	6
td	3
td	0
td	358.374
tr	52 CID: 58659189 4.291 78.002 446.382 6 3 0 386.805
td	52
td	CID: 58659189
td	4.291
td	78.002
td	446.382
td	6
td	3
td	0
td	386.805
tr	53 CID: 72986690 4.357 78.002 450.345 6 3 0 375.175
td	53
td	CID: 72986690
td	4.357
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	54 CID: 11502981 5.581 65.975 435.33 5 2 1 362.773
td	54
td	CID: 11502981
td	5.581
td	65.975
td	435.33
td	5
td	2
td	1
td	362.773
tr	55 CID: 11676140 4.842 65.975 421.303 5 2 0 345.971
td	55
td	CID: 11676140
td	4.842
td	65.975
td	421.303
td	5
td	2
td	0
td	345.971
tr	56 CID: 58659141 4.939 75.209 465.356 6 2 0 388.56
td	56
td	CID: 58659141
td	4.939
td	75.209
td	465.356
td	6
td	2
td	0
td	388.56
tr	57 CID: 11705849 4.978 69.213 490.41 6 2 0 414.932
td	57
td	CID: 11705849
td	4.978
td	69.213
td	490.41
td	6
td	2
td	0
td	414.932
tr	58 CID: 11719356 3.956 78.002 450.345 6 3 0 375.175
td	58
td	CID: 11719356
td	3.956
td	78.002
td	450.345
td	6
td	3
td	0
td	375.175
tr	59 CID: 11647759 4.199 78.002 436.318 6 3 0 358.374
td	59
td	CID: 11647759
td	4.199
td	78.002
td	436.318
td	6
td	3
td	0
td	358.374
tr	60 CID: 21110753 4.058 78.447 480.371 7 2 0 401.318
td	60
td	CID: 21110753
td	4.058
td	78.447
td	480.371
td	7
td	2
td	0
td	401.318
tr	61 CID: 58659185 5.304 65.975 423.319 5 2 1 356.331
td	61
td	CID: 58659185
td	5.304
td	65.975
td	423.319
td	5
td	2
td	1
td	356.331
tr	62 CID: 21110757 4.182 65.975 381.238 5 2 0 306.141
td	62
td	CID: 21110757
td	4.182
td	65.975
td	381.238
td	5
td	2
td	0
td	306.141
tr	63 CID: 73386634 4.182 65.975 381.238 5 2 0 306.141
td	63
td	CID: 73386634
td	4.182
td	65.975
td	381.238
td	5
td	2
td	0
td	306.141
tr	64 CID: 11647795 4.285 75.209 437.302 6 2 0 354.956
td	64
td	CID: 11647795
td	4.285
td	75.209
td	437.302
td	6
td	2
td	0
td	354.956
table-wrap-foot	Bold indicates ADME screened compounds based on Lipinsiki rule of 5
p	Bold indicates ADME screened compounds based on Lipinsiki rule of 5
p	It is bare that for passing oral bioavailability criteria, number of rotatable bond should be <10 (Oprea 2000). Therefore, we have made the further refinement of these hits by restricting the number of rotatable bonds to 10. The result is presented in Table 2. It is clear from the Table 2 that almost all the 60 compounds screened from the ADME analysis possess reasonable number of rotatable bonds (<10). This result indicates that these compounds may have the potential to become a lead compound. However, toxicity is also one of the important issue could be addressed for all the lead compounds before its selection. Table 2 Details of number of rotatable bonds S. no Compound nrotb 1 Crizotinib 5 2 CID: 11597571 5 3 CID: 11626560 5 4 CID: 53234260 5 5 CID: 53234326 5 6 CID: 56671814 5 7 CID: 60197531 5 8 CID: 60197626 5 9 CID: 60198523 5 10 CID: 60198524 5 11 CID: 60198525 5 12 CID: 60199015 5 13 CID: 60199016 5 14 CID: 60199073 5 15 CID: 60199075 5 16 CID: 60199076 5 17 CID: 60199077 5 18 CID: 62705017 5 19 CID: 68625002 6 20 CID: 54613769 5 21 CID: 11662380 5 22 CID: 11626823 6 23 CID: 58659191 5 24 CID: 44560358 5 25 CID: 71239831 5 26 CID: 71239833 5 27 CID: 71240010 5 28 CID: 71240011 5 29 CID: 11496366 5 30 CID: 11562021 6 31 CID: 11626824 5 32 CID: 11598102 5 33 CID: 11641497 7 34 CID: 11690598 5 35 CID: 68563708 5 36 CID: 11562217 5 37 CID: 11612136 5 38 CID: 58659130 5 39 CID: 11625675 5 40 CID: 67084493 6 41 CID: 11676204 7 42 CID: 11684380 6 43 CID: 58659192 5 44 CID: 58659228 5 45 CID: 11503318 6 46 CID: 11510387 5 47 CID: 11568619 6 48 CID: 11575401 5 49 CID: 11647760 5 50 CID: 58659136 5 51 CID: 58659189 5 52 CID: 72986690 6 53 CID: 11676140 5 54 CID: 58659141 6 55 CID: 11705849 5 56 CID: 11719356 5 57 CID: 11647759 6 58 CID: 21110753 7 59 CID: 21110757 4 60 CID: 73386634 4 61 CID: 11647795 5 Number of rotatable bonds <10
table-wrap	Table 2 Details of number of rotatable bonds S. no Compound nrotb 1 Crizotinib 5 2 CID: 11597571 5 3 CID: 11626560 5 4 CID: 53234260 5 5 CID: 53234326 5 6 CID: 56671814 5 7 CID: 60197531 5 8 CID: 60197626 5 9 CID: 60198523 5 10 CID: 60198524 5 11 CID: 60198525 5 12 CID: 60199015 5 13 CID: 60199016 5 14 CID: 60199073 5 15 CID: 60199075 5 16 CID: 60199076 5 17 CID: 60199077 5 18 CID: 62705017 5 19 CID: 68625002 6 20 CID: 54613769 5 21 CID: 11662380 5 22 CID: 11626823 6 23 CID: 58659191 5 24 CID: 44560358 5 25 CID: 71239831 5 26 CID: 71239833 5 27 CID: 71240010 5 28 CID: 71240011 5 29 CID: 11496366 5 30 CID: 11562021 6 31 CID: 11626824 5 32 CID: 11598102 5 33 CID: 11641497 7 34 CID: 11690598 5 35 CID: 68563708 5 36 CID: 11562217 5 37 CID: 11612136 5 38 CID: 58659130 5 39 CID: 11625675 5 40 CID: 67084493 6 41 CID: 11676204 7 42 CID: 11684380 6 43 CID: 58659192 5 44 CID: 58659228 5 45 CID: 11503318 6 46 CID: 11510387 5 47 CID: 11568619 6 48 CID: 11575401 5 49 CID: 11647760 5 50 CID: 58659136 5 51 CID: 58659189 5 52 CID: 72986690 6 53 CID: 11676140 5 54 CID: 58659141 6 55 CID: 11705849 5 56 CID: 11719356 5 57 CID: 11647759 6 58 CID: 21110753 7 59 CID: 21110757 4 60 CID: 73386634 4 61 CID: 11647795 5 Number of rotatable bonds <10
label	Table 2
caption	Details of number of rotatable bonds
p	Details of number of rotatable bonds
table	S. no Compound nrotb 1 Crizotinib 5 2 CID: 11597571 5 3 CID: 11626560 5 4 CID: 53234260 5 5 CID: 53234326 5 6 CID: 56671814 5 7 CID: 60197531 5 8 CID: 60197626 5 9 CID: 60198523 5 10 CID: 60198524 5 11 CID: 60198525 5 12 CID: 60199015 5 13 CID: 60199016 5 14 CID: 60199073 5 15 CID: 60199075 5 16 CID: 60199076 5 17 CID: 60199077 5 18 CID: 62705017 5 19 CID: 68625002 6 20 CID: 54613769 5 21 CID: 11662380 5 22 CID: 11626823 6 23 CID: 58659191 5 24 CID: 44560358 5 25 CID: 71239831 5 26 CID: 71239833 5 27 CID: 71240010 5 28 CID: 71240011 5 29 CID: 11496366 5 30 CID: 11562021 6 31 CID: 11626824 5 32 CID: 11598102 5 33 CID: 11641497 7 34 CID: 11690598 5 35 CID: 68563708 5 36 CID: 11562217 5 37 CID: 11612136 5 38 CID: 58659130 5 39 CID: 11625675 5 40 CID: 67084493 6 41 CID: 11676204 7 42 CID: 11684380 6 43 CID: 58659192 5 44 CID: 58659228 5 45 CID: 11503318 6 46 CID: 11510387 5 47 CID: 11568619 6 48 CID: 11575401 5 49 CID: 11647760 5 50 CID: 58659136 5 51 CID: 58659189 5 52 CID: 72986690 6 53 CID: 11676140 5 54 CID: 58659141 6 55 CID: 11705849 5 56 CID: 11719356 5 57 CID: 11647759 6 58 CID: 21110753 7 59 CID: 21110757 4 60 CID: 73386634 4 61 CID: 11647795 5
tr	S. no Compound nrotb
th	S. no
th	Compound
th	nrotb
tr	1 Crizotinib 5
td	1
td	Crizotinib
td	5
tr	2 CID: 11597571 5
td	2
td	CID: 11597571
td	5
tr	3 CID: 11626560 5
td	3
td	CID: 11626560
td	5
tr	4 CID: 53234260 5
td	4
td	CID: 53234260
td	5
tr	5 CID: 53234326 5
td	5
td	CID: 53234326
td	5
tr	6 CID: 56671814 5
td	6
td	CID: 56671814
td	5
tr	7 CID: 60197531 5
td	7
td	CID: 60197531
td	5
tr	8 CID: 60197626 5
td	8
td	CID: 60197626
td	5
tr	9 CID: 60198523 5
td	9
td	CID: 60198523
td	5
tr	10 CID: 60198524 5
td	10
td	CID: 60198524
td	5
tr	11 CID: 60198525 5
td	11
td	CID: 60198525
td	5
tr	12 CID: 60199015 5
td	12
td	CID: 60199015
td	5
tr	13 CID: 60199016 5
td	13
td	CID: 60199016
td	5
tr	14 CID: 60199073 5
td	14
td	CID: 60199073
td	5
tr	15 CID: 60199075 5
td	15
td	CID: 60199075
td	5
tr	16 CID: 60199076 5
td	16
td	CID: 60199076
td	5
tr	17 CID: 60199077 5
td	17
td	CID: 60199077
td	5
tr	18 CID: 62705017 5
td	18
td	CID: 62705017
td	5
tr	19 CID: 68625002 6
td	19
td	CID: 68625002
td	6
tr	20 CID: 54613769 5
td	20
td	CID: 54613769
td	5
tr	21 CID: 11662380 5
td	21
td	CID: 11662380
td	5
tr	22 CID: 11626823 6
td	22
td	CID: 11626823
td	6
tr	23 CID: 58659191 5
td	23
td	CID: 58659191
td	5
tr	24 CID: 44560358 5
td	24
td	CID: 44560358
td	5
tr	25 CID: 71239831 5
td	25
td	CID: 71239831
td	5
tr	26 CID: 71239833 5
td	26
td	CID: 71239833
td	5
tr	27 CID: 71240010 5
td	27
td	CID: 71240010
td	5
tr	28 CID: 71240011 5
td	28
td	CID: 71240011
td	5
tr	29 CID: 11496366 5
td	29
td	CID: 11496366
td	5
tr	30 CID: 11562021 6
td	30
td	CID: 11562021
td	6
tr	31 CID: 11626824 5
td	31
td	CID: 11626824
td	5
tr	32 CID: 11598102 5
td	32
td	CID: 11598102
td	5
tr	33 CID: 11641497 7
td	33
td	CID: 11641497
td	7
tr	34 CID: 11690598 5
td	34
td	CID: 11690598
td	5
tr	35 CID: 68563708 5
td	35
td	CID: 68563708
td	5
tr	36 CID: 11562217 5
td	36
td	CID: 11562217
td	5
tr	37 CID: 11612136 5
td	37
td	CID: 11612136
td	5
tr	38 CID: 58659130 5
td	38
td	CID: 58659130
td	5
tr	39 CID: 11625675 5
td	39
td	CID: 11625675
td	5
tr	40 CID: 67084493 6
td	40
td	CID: 67084493
td	6
tr	41 CID: 11676204 7
td	41
td	CID: 11676204
td	7
tr	42 CID: 11684380 6
td	42
td	CID: 11684380
td	6
tr	43 CID: 58659192 5
td	43
td	CID: 58659192
td	5
tr	44 CID: 58659228 5
td	44
td	CID: 58659228
td	5
tr	45 CID: 11503318 6
td	45
td	CID: 11503318
td	6
tr	46 CID: 11510387 5
td	46
td	CID: 11510387
td	5
tr	47 CID: 11568619 6
td	47
td	CID: 11568619
td	6
tr	48 CID: 11575401 5
td	48
td	CID: 11575401
td	5
tr	49 CID: 11647760 5
td	49
td	CID: 11647760
td	5
tr	50 CID: 58659136 5
td	50
td	CID: 58659136
td	5
tr	51 CID: 58659189 5
td	51
td	CID: 58659189
td	5
tr	52 CID: 72986690 6
td	52
td	CID: 72986690
td	6
tr	53 CID: 11676140 5
td	53
td	CID: 11676140
td	5
tr	54 CID: 58659141 6
td	54
td	CID: 58659141
td	6
tr	55 CID: 11705849 5
td	55
td	CID: 11705849
td	5
tr	56 CID: 11719356 5
td	56
td	CID: 11719356
td	5
tr	57 CID: 11647759 6
td	57
td	CID: 11647759
td	6
tr	58 CID: 21110753 7
td	58
td	CID: 21110753
td	7
tr	59 CID: 21110757 4
td	59
td	CID: 21110757
td	4
tr	60 CID: 73386634 4
td	60
td	CID: 73386634
td	4
tr	61 CID: 11647795 5
td	61
td	CID: 11647795
td	5
table-wrap-foot	Number of rotatable bonds <10
p	Number of rotatable bonds <10
sec	Toxicity analysis The primary objective behind the failure of the majority of compounds in drug discovery process is the issues related to pharmacokinetics and toxicity. In the present investigation, these issues were addressed with the help of OSIRIS property explorer program. The pharmacokinetic property of a lead compound can be investigated by utilizing the parameters such as clogP and logS. The result is shown in Table 3. clogP is an entrenched measure of the compound’s hydrophilicity. The high log P values may cause poor retention because of the compound’s low hydrophilicity. It has been demonstrated that for compounds to have a reasonable probability of being well absorbed, their log P value must not be greater than 5.0. It is clear from the table that log P values of all the 60 compounds found to be in the acceptable criteria. Table 3 Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score 1 Crizotinib No No No 3.54 −5.26 3.12 0.52 2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52 3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52 4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52 5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52 6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52 7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52 8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52 9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52 10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52 11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52 12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52 13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52 14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52 15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52 16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52 17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52 18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52 19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46 20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53 21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42 22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48 23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29 24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54 25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38 26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37 27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38 28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38 29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54 30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48 31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54 32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41 33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49 34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6 35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6 36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29 37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33 38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60 39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53 40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37 41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62 42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54 43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22 44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53 45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42 46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47 47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42 48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63 49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58 50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48 51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31 52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42 53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44 54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33 55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42 56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53 57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57 58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59 59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56 60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56 61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48 Drug solubility normally affects the absorption and distribution characteristics of a compound. Infact, insufficient solubility of drug can lead to poor absorption (Lipinski et al. 1997). Our evaluated log S worth is a unit stripped logarithm (base 10) of a compound’s dissolvability measured in mol/liter. There are more than 80 % of the drugs available in the market have an (expected) log S value greater than −4. It is clear from the Table 3 that the solubility of the 60 lead compounds was found in the comparable zone with that of standard drugs to fulfill the requirements of solubility and this could be regarded as a candidate drug for oral absorption.
title	Toxicity analysis
p	The primary objective behind the failure of the majority of compounds in drug discovery process is the issues related to pharmacokinetics and toxicity. In the present investigation, these issues were addressed with the help of OSIRIS property explorer program. The pharmacokinetic property of a lead compound can be investigated by utilizing the parameters such as clogP and logS. The result is shown in Table 3. clogP is an entrenched measure of the compound’s hydrophilicity. The high log P values may cause poor retention because of the compound’s low hydrophilicity. It has been demonstrated that for compounds to have a reasonable probability of being well absorbed, their log P value must not be greater than 5.0. It is clear from the table that log P values of all the 60 compounds found to be in the acceptable criteria. Table 3 Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score 1 Crizotinib No No No 3.54 −5.26 3.12 0.52 2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52 3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52 4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52 5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52 6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52 7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52 8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52 9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52 10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52 11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52 12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52 13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52 14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52 15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52 16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52 17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52 18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52 19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46 20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53 21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42 22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48 23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29 24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54 25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38 26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37 27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38 28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38 29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54 30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48 31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54 32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41 33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49 34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6 35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6 36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29 37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33 38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60 39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53 40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37 41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62 42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54 43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22 44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53 45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42 46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47 47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42 48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63 49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58 50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48 51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31 52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42 53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44 54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33 55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42 56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53 57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57 58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59 59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56 60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56 61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48
table-wrap	Table 3 Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score 1 Crizotinib No No No 3.54 −5.26 3.12 0.52 2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52 3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52 4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52 5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52 6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52 7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52 8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52 9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52 10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52 11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52 12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52 13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52 14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52 15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52 16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52 17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52 18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52 19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46 20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53 21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42 22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48 23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29 24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54 25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38 26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37 27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38 28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38 29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54 30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48 31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54 32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41 33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49 34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6 35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6 36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29 37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33 38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60 39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53 40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37 41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62 42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54 43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22 44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53 45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42 46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47 47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42 48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63 49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58 50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48 51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31 52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42 53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44 54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33 55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42 56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53 57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57 58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59 59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56 60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56 61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48
label	Table 3
caption	Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer
p	Toxicity risks and physicochemical properties of crizotinib and virtual compounds predicted by OSIRIS property explorer
table	S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score 1 Crizotinib No No No 3.54 −5.26 3.12 0.52 2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52 3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52 4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52 5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52 6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52 7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52 8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52 9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52 10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52 11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52 12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52 13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52 14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52 15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52 16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52 17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52 18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52 19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46 20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53 21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42 22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48 23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29 24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54 25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38 26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37 27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38 28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38 29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54 30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48 31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54 32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41 33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49 34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6 35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6 36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29 37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33 38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60 39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53 40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37 41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62 42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54 43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22 44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53 45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42 46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47 47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42 48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63 49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58 50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48 51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31 52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42 53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44 54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33 55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42 56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53 57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57 58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59 59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56 60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56 61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48
tr	S. no Compound ID Mutagenic Tumorigenic Reproductive effective cLogP Solubility Drug likeness Drug score
th	S. no
th	Compound ID
th	Mutagenic
th	Tumorigenic
th	Reproductive effective
th	cLogP
th	Solubility
th	Drug likeness
th	Drug score
tr	1 Crizotinib No No No 3.54 −5.26 3.12 0.52
td	1
td	Crizotinib
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	2 CID: 11597571 No No No 3.54 −5.26 3.12 0.52
td	2
td	CID: 11597571
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	3 CID: 11626560 No No No 3.54 −5.26 3.12 0.52
td	3
td	CID: 11626560
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	4 CID: 53234260 No No No 3.54 −5.26 3.12 0.52
td	4
td	CID: 53234260
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	5 CID: 53234326 No No No 3.54 −5.26 3.12 0.52
td	5
td	CID: 53234326
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	6 CID: 56671814 No No No 3.54 −5.26 3.12 0.52
td	6
td	CID: 56671814
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	7 CID: 60197531 No No No 3.54 −5.26 3.12 0.52
td	7
td	CID: 60197531
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	8 CID: 60197626 No No No 3.54 −5.26 3.12 0.52
td	8
td	CID: 60197626
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	9 CID: 60198523 No No No 3.54 −5.26 3.12 0.52
td	9
td	CID: 60198523
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	10 CID: 60198524 No No No 3.54 −5.26 3.12 0.52
td	10
td	CID: 60198524
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	11 CID: 60198525 No No No 3.54 −5.26 3.12 0.52
td	11
td	CID: 60198525
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	12 CID: 60199015 No No No 3.54 −5.26 3.12 0.52
td	12
td	CID: 60199015
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	13 CID: 60199016 No No No 3.54 −5.26 3.12 0.52
td	13
td	CID: 60199016
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	14 CID: 60199073 No No No 3.54 −5.26 3.12 0.52
td	14
td	CID: 60199073
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	15 CID: 60199075 No No No 3.54 −5.26 3.12 0.52
td	15
td	CID: 60199075
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	16 CID: 60199076 No No No 3.54 −5.26 3.12 0.52
td	16
td	CID: 60199076
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	17 CID: 60199077 No No No 3.54 −5.26 3.12 0.52
td	17
td	CID: 60199077
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	18 CID: 62705017 No No No 3.54 −5.26 3.12 0.52
td	18
td	CID: 62705017
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.12
td	0.52
tr	19 CID: 68625002 No No No 3.78 −5.69 3.68 0.46
td	19
td	CID: 68625002
td	No
td	No
td	No
td	3.78
td	−5.69
td	3.68
td	0.46
tr	20 CID: 54613769 No No No 3.54 −5.26 3.22 0.53
td	20
td	CID: 54613769
td	No
td	No
td	No
td	3.54
td	−5.26
td	3.22
td	0.53
tr	21 CID: 11662380 No No Yes 3.54 −5.26 2.78 0.42
td	21
td	CID: 11662380
td	No
td	No
td	Yes
td	3.54
td	−5.26
td	2.78
td	0.42
tr	22 CID: 11626823 No No No 3.29 −5.78 3.45 0.48
td	22
td	CID: 11626823
td	No
td	No
td	No
td	3.29
td	−5.78
td	3.45
td	0.48
tr	23 CID: 58659191 No Yes No 3.64 −5.58 3.17 0.29
td	23
td	CID: 58659191
td	No
td	Yes
td	No
td	3.64
td	−5.58
td	3.17
td	0.29
tr	24 CID: 44560358 No No No 3.25 −5.19 2.42 0.54
td	24
td	CID: 44560358
td	No
td	No
td	No
td	3.25
td	−5.19
td	2.42
td	0.54
tr	25 CID: 71239831 No No No 4.19 −5.96 1.79 0.38
td	25
td	CID: 71239831
td	No
td	No
td	No
td	4.19
td	−5.96
td	1.79
td	0.38
tr	26 CID: 71239833 No No No 4.19 −5.96 1.45 0.37
td	26
td	CID: 71239833
td	No
td	No
td	No
td	4.19
td	−5.96
td	1.45
td	0.37
tr	27 CID: 71240010 No No No 4.19 −5.96 1.79 0.38
td	27
td	CID: 71240010
td	No
td	No
td	No
td	4.19
td	−5.96
td	1.79
td	0.38
tr	28 CID: 71240011 No No No 4.19 −5.96 1.79 0.38
td	28
td	CID: 71240011
td	No
td	No
td	No
td	4.19
td	−5.96
td	1.79
td	0.38
tr	29 CID: 11496366 No No No 3.79 −4.90 7.62 0.54
td	29
td	CID: 11496366
td	No
td	No
td	No
td	3.79
td	−4.90
td	7.62
td	0.54
tr	30 CID: 11562021 No No No 4.2 −5.22 7.51 0.48
td	30
td	CID: 11562021
td	No
td	No
td	No
td	4.2
td	−5.22
td	7.51
td	0.48
tr	31 CID: 11626824 No No No 3.79 −4.90 7.62 0.54
td	31
td	CID: 11626824
td	No
td	No
td	No
td	3.79
td	−4.90
td	7.62
td	0.54
tr	32 CID: 11598102 No No No 3.89 −6.11 2.11 0.41
td	32
td	CID: 11598102
td	No
td	No
td	No
td	3.89
td	−6.11
td	2.11
td	0.41
tr	33 CID: 11641497 No No No 2.38 −4.53 4.34 0.49
td	33
td	CID: 11641497
td	No
td	No
td	No
td	2.38
td	−4.53
td	4.34
td	0.49
tr	34 CID: 11690598 No No No 3.03 −4.84 3.12 0.6
td	34
td	CID: 11690598
td	No
td	No
td	No
td	3.03
td	−4.84
td	3.12
td	0.6
tr	35 CID: 68563708 No No No 3.03 −4.84 3.12 0.6
td	35
td	CID: 68563708
td	No
td	No
td	No
td	3.03
td	−4.84
td	3.12
td	0.6
tr	36 CID: 11562217 No No No 3.44 −5.35 2.82 0.29
td	36
td	CID: 11562217
td	No
td	No
td	No
td	3.44
td	−5.35
td	2.82
td	0.29
tr	37 CID: 11612136 No No No 3.68 −5.4 −0.93 0.33
td	37
td	CID: 11612136
td	No
td	No
td	No
td	3.68
td	−5.4
td	−0.93
td	0.33
tr	38 CID: 58659130 No No No 3.03 −4.84 3.22 0.60
td	38
td	CID: 58659130
td	No
td	No
td	No
td	3.03
td	−4.84
td	3.22
td	0.60
tr	39 CID: 11625675 No No No 3.75 −5.39 2.56 0.53
td	39
td	CID: 11625675
td	No
td	No
td	No
td	3.75
td	−5.39
td	2.56
td	0.53
tr	40 CID: 67084493 No No No 4.04 −6.15 1.21 0.37
td	40
td	CID: 67084493
td	No
td	No
td	No
td	4.04
td	−6.15
td	1.21
td	0.37
tr	41 CID: 11676204 No No No 2.28 −4.96 3.76 0.62
td	41
td	CID: 11676204
td	No
td	No
td	No
td	2.28
td	−4.96
td	3.76
td	0.62
tr	42 CID: 11684380 No No No 3.55 −5.42 7.62 0.54
td	42
td	CID: 11684380
td	No
td	No
td	No
td	3.55
td	−5.42
td	7.62
td	0.54
tr	43 CID: 58659192 No Yes No 4 −6.42 2.17 0.22
td	43
td	CID: 58659192
td	No
td	Yes
td	No
td	4
td	−6.42
td	2.17
td	0.22
tr	44 CID: 59599446 No No No 2.47 −5.33 4.07 0.53
td	44
td	CID: 59599446
td	No
td	No
td	No
td	2.47
td	−5.33
td	4.07
td	0.53
tr	45 CID: 11503318 No No No 3.01 −5.73 0.63 0.42
td	45
td	CID: 11503318
td	No
td	No
td	No
td	3.01
td	−5.73
td	0.63
td	0.42
tr	46 CID: 11510387 No No No 3.30 −6.39 3.37 0.47
td	46
td	CID: 11510387
td	No
td	No
td	No
td	3.30
td	−6.39
td	3.37
td	0.47
tr	47 CID: 11568619 No No No 3.01 −5.73 0.63 0.42
td	47
td	CID: 11568619
td	No
td	No
td	No
td	3.01
td	−5.73
td	0.63
td	0.42
tr	48 CID: 11575401 No No No 2.85 −4.72 3.34 0.63
td	48
td	CID: 11575401
td	No
td	No
td	No
td	2.85
td	−4.72
td	3.34
td	0.63
tr	49 CID: 11647760 No No No 3.20 −4.99 3.81 0.58
td	49
td	CID: 11647760
td	No
td	No
td	No
td	3.20
td	−4.99
td	3.81
td	0.58
tr	50 CID: 58659136 No No No 3.20 −4.99 3.81 0.48
td	50
td	CID: 58659136
td	No
td	No
td	No
td	3.20
td	−4.99
td	3.81
td	0.48
tr	51 CID: 58659189 Yes No No 3.78 −5.29 4.46 0.31
td	51
td	CID: 58659189
td	Yes
td	No
td	No
td	3.78
td	−5.29
td	4.46
td	0.31
tr	52 CID: 72986690 No No No 3.01 −5.73 0.63 0.42
td	52
td	CID: 72986690
td	No
td	No
td	No
td	3.01
td	−5.73
td	0.63
td	0.42
tr	53 CID: 11676140 No No No 4.16 −5.75 1.66 0.44
td	53
td	CID: 11676140
td	No
td	No
td	No
td	4.16
td	−5.75
td	1.66
td	0.44
tr	54 CID: 58659141 No No No 3.44 −5.91 −0.32 0.33
td	54
td	CID: 58659141
td	No
td	No
td	No
td	3.44
td	−5.91
td	−0.32
td	0.33
tr	55 CID: 11705849 No No No 4.15 −5.74 2.96 0.42
td	55
td	CID: 11705849
td	No
td	No
td	No
td	4.15
td	−5.74
td	2.96
td	0.42
tr	56 CID: 11719356 No No No 3.63 −4.96 2.31 0.53
td	56
td	CID: 11719356
td	No
td	No
td	No
td	3.63
td	−4.96
td	2.31
td	0.53
tr	57 CID: 11647759 No No No 2.61 −5.24 3.45 0.57
td	57
td	CID: 11647759
td	No
td	No
td	No
td	2.61
td	−5.24
td	3.45
td	0.57
tr	58 CID: 21110753 No No No 2.52 −4.67 3.67 0.59
td	58
td	CID: 21110753
td	No
td	No
td	No
td	2.52
td	−4.67
td	3.67
td	0.59
tr	59 CID: 21110757 No No No 3.00 −5.47 2.35 0.56
td	59
td	CID: 21110757
td	No
td	No
td	No
td	3.00
td	−5.47
td	2.35
td	0.56
tr	60 CID: 73386634 No No No 3.00 −5.47 2.35 0.56
td	60
td	CID: 73386634
td	No
td	No
td	No
td	3.00
td	−5.47
td	2.35
td	0.56
tr	61 CID: 11647795 No No No 3.34 −5.13 0.85 0.48
td	61
td	CID: 11647795
td	No
td	No
td	No
td	3.34
td	−5.13
td	0.85
td	0.48
p	Drug solubility normally affects the absorption and distribution characteristics of a compound. Infact, insufficient solubility of drug can lead to poor absorption (Lipinski et al. 1997). Our evaluated log S worth is a unit stripped logarithm (base 10) of a compound’s dissolvability measured in mol/liter. There are more than 80 % of the drugs available in the market have an (expected) log S value greater than −4. It is clear from the Table 3 that the solubility of the 60 lead compounds was found in the comparable zone with that of standard drugs to fulfill the requirements of solubility and this could be regarded as a candidate drug for oral absorption.
sec	Drug likeness The drug likeliness is imperative parameter because drug like molecules exhibit favorable absorption, distribution, metabolism, excretion, toxicological (ADMET) parameters (Tetko 2005). In this study, Osiris program was utilized to calculate the drug-likeness of crizotinib and other virtually screened compounds (Sander 2001). It is worth stressing that the drug likeness value of 60 lead compounds was found to be in acceptable criteria.
title	Drug likeness
p	The drug likeliness is imperative parameter because drug like molecules exhibit favorable absorption, distribution, metabolism, excretion, toxicological (ADMET) parameters (Tetko 2005). In this study, Osiris program was utilized to calculate the drug-likeness of crizotinib and other virtually screened compounds (Sander 2001). It is worth stressing that the drug likeness value of 60 lead compounds was found to be in acceptable criteria.
sec	Drug score and toxicity The information assessed in Table 3 shows that the 57 lead compounds should be non-mutagenic and non-tumorigenic impacts when run through the mutagenicity assessment system comparable with standard drugs used. The compounds such as CID: 11662380, CID: 58659189, CID: 58659191, and CID: 58659192 failed to pass through the Osiris program and showed mutagenic and tumorigenic effects. We have also analyzed the overall drug score (DS) for all the lead compounds and compared with that of crizotinib. The score consolidates drug- likeness, miLogP, logS, molecular weight, and toxicity risks. The DS score could also be an important parameter to judge the compound’s potential to meet all requirements to qualify for a drug. The result is demonstrated in Table 3. The reported lead compounds demonstrated moderate to good DS as compared with standard drug crizotinib. In our dataset, 17 lead compounds showed similar drug score as that of crizotinib. About five compounds such as CID: 11690598, CID: 68563708, CID: 58659130, CID: 11676204 and CID: 11575401 showed a drug score of 0.6 and above. Therefore, further examination was carried out with 57 compounds.
title	Drug score and toxicity
p	The information assessed in Table 3 shows that the 57 lead compounds should be non-mutagenic and non-tumorigenic impacts when run through the mutagenicity assessment system comparable with standard drugs used. The compounds such as CID: 11662380, CID: 58659189, CID: 58659191, and CID: 58659192 failed to pass through the Osiris program and showed mutagenic and tumorigenic effects. We have also analyzed the overall drug score (DS) for all the lead compounds and compared with that of crizotinib. The score consolidates drug- likeness, miLogP, logS, molecular weight, and toxicity risks. The DS score could also be an important parameter to judge the compound’s potential to meet all requirements to qualify for a drug. The result is demonstrated in Table 3. The reported lead compounds demonstrated moderate to good DS as compared with standard drug crizotinib. In our dataset, 17 lead compounds showed similar drug score as that of crizotinib. About five compounds such as CID: 11690598, CID: 68563708, CID: 58659130, CID: 11676204 and CID: 11575401 showed a drug score of 0.6 and above. Therefore, further examination was carried out with 57 compounds.
sec	Molecular docking Molecular docking program was employed to find out the binding affinity of lead compounds with the target protein. Docking analysis was performed twice to eliminate the false positive. The docking results are shown in Table 4. The docking score of native-type ALK-crizotinib complex was found to be 5312 and for the mutant-type ALK-crizotinib complex was found to be 4602. The lesser docking score of mutant complex clearly indicates that double mutation (L1196M and G1269A) significantly affects the binding of crizotinib with the ALK structures. It is believed that a potential lead compound is the one should have higher docking scoring than the existing drug molecule, crizotinib. Therefore, we have examined docking score for all the 57 hits both with the native type and with mutant type ALK systems. 16 hits showed higher docking score only with mutant type ALK than native type ALK and 17 more hits from our dataset showed similar dock score to that of crizotinib. Most importantly, 10 hits from our dataset showed higher score both in the native type as well as with mutant type. For instance, CID 11562217 molecule showed the highest docking score among the 10 hits in our data set. The docking score of native-type ALK-CID 11562217 complex was found to be 5662 and for the mutant-type ALK-CID 11562217 complex was found to be 5908. This result indicates that CID 11562217 has a better binding affinity not only with the native type but also with mutant ALK as compared to the crizotinib. Table 4 Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure S. no Compound ID Score 2XP2 4ANS 1 Crizotinib 5312 5226 2 CID: 11597571 5312 5226 3 CID: 11626560 5312 5226 4 CID: 53234260 5312 5226 5 CID: 53234326 5312 5226 6 CID: 56671814 5312 5226 7 CID: 60197531 5312 5226 8 CID: 60197626 5312 5226 9 CID: 60198523 5312 5226 10 CID: 60198524 5312 5226 11 CID: 60198525 5312 5226 12 CID: 60199015 5312 5226 13 CID: 60199016 5312 5226 14 CID: 60199073 5312 5226 15 CID: 60199075 5312 5226 16 CID: 60199076 5312 5226 17 CID: 60199077 5312 5226 18 CID: 62705017 5312 5226 19 CID: 68625002 5200 5342 20 CID: 54613769 5298 5308 21 CID: 11626823 5048 5226 22 CID: 44560358 5012 5386 23 CID: 71239831 5440 5776 24 CID: 71239833 5440 5776 25 CID: 71240010 5426 5504 26 CID: 71240011 5426 5504 27 CID: 11496366 5412 5420 28 CID: 11562021 5510 5492 29 CID: 11626824 5412 5420 30 CID: 11598102 5292 5294 31 CID: 11641497 5450 5138 32 CID: 11690598 4906 5138 33 CID: 68563708 4906 5138 34 CID: 11562217 5662 5908 35 CID: 11612136 5144 5032 36 CID: 58659130 5108 5294 37 CID: 11625675 4746 5052 38 CID: 67084493 4950 5334 39 CID: 11676204 4964 4962 40 CID: 11684380 4964 5424 41 CID: 59599446 5434 5704 42 CID: 11503318 5110 5138 43 CID: 11510387 5124 5372 44 CID: 11568619 5110 5138 45 CID: 11575401 4886 4826 46 CID: 11647760 5124 5372 47 CID: 58659136 5124 5372 48 CID: 72986690 5110 5138 49 CID: 11676140 4906 5484 50 CID: 58659141 5118 5278 51 CID: 11705849 5186 5370 52 CID: 11719356 5040 5238 53 CID: 11647759 5026 5118 54 CID: 21110753 5390 5526 55 CID: 21110757 4408 4604 56 CID: 73386634 4408 4604 57 CID: 11647795 5268 5212 Bold indicates the lead compounds showed higher binding score than crizotinib It is also to be noted that the pharmacokinetic and pharmacodynamic investigation of CID 11562217 indicated better results than the other lead compounds explored in our study (Fig. 2). The two dimensional structure of crizotinib was compared with CID 11562217 to get the structural attributes and the result is demonstrated in Fig. 3. It demonstrates that CID11562217 is a nitrile enhanced crizotinib. It is worth stressing that nitrile compounds with cyanide functional group could possess potential anti-tumor effects (US Patent 20060128724). The literature evidence also highlights that our lead molecule has kinase inhibiting effects. Further, the cyano-containing analogues were able to produce DNA–DNA cross-linking. The reduced DNA cross-linking was paralleled by a similar reduction in cytotoxicity indicating a relationship between cross-linking and anti-tumor effect (Jesson et al. 1987). Therefore, further validation of CID 11562217 compound was done with the help of molecular dynamics simulation study. Fig. 2 Osiris property explorer showing drug-likeliness properties of CID11562217 Fig. 3 Structure comparison between (a) crizotinib and (b) CID11562217
title	Molecular docking
p	Molecular docking program was employed to find out the binding affinity of lead compounds with the target protein. Docking analysis was performed twice to eliminate the false positive. The docking results are shown in Table 4. The docking score of native-type ALK-crizotinib complex was found to be 5312 and for the mutant-type ALK-crizotinib complex was found to be 4602. The lesser docking score of mutant complex clearly indicates that double mutation (L1196M and G1269A) significantly affects the binding of crizotinib with the ALK structures. It is believed that a potential lead compound is the one should have higher docking scoring than the existing drug molecule, crizotinib. Therefore, we have examined docking score for all the 57 hits both with the native type and with mutant type ALK systems. 16 hits showed higher docking score only with mutant type ALK than native type ALK and 17 more hits from our dataset showed similar dock score to that of crizotinib. Most importantly, 10 hits from our dataset showed higher score both in the native type as well as with mutant type. For instance, CID 11562217 molecule showed the highest docking score among the 10 hits in our data set. The docking score of native-type ALK-CID 11562217 complex was found to be 5662 and for the mutant-type ALK-CID 11562217 complex was found to be 5908. This result indicates that CID 11562217 has a better binding affinity not only with the native type but also with mutant ALK as compared to the crizotinib. Table 4 Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure S. no Compound ID Score 2XP2 4ANS 1 Crizotinib 5312 5226 2 CID: 11597571 5312 5226 3 CID: 11626560 5312 5226 4 CID: 53234260 5312 5226 5 CID: 53234326 5312 5226 6 CID: 56671814 5312 5226 7 CID: 60197531 5312 5226 8 CID: 60197626 5312 5226 9 CID: 60198523 5312 5226 10 CID: 60198524 5312 5226 11 CID: 60198525 5312 5226 12 CID: 60199015 5312 5226 13 CID: 60199016 5312 5226 14 CID: 60199073 5312 5226 15 CID: 60199075 5312 5226 16 CID: 60199076 5312 5226 17 CID: 60199077 5312 5226 18 CID: 62705017 5312 5226 19 CID: 68625002 5200 5342 20 CID: 54613769 5298 5308 21 CID: 11626823 5048 5226 22 CID: 44560358 5012 5386 23 CID: 71239831 5440 5776 24 CID: 71239833 5440 5776 25 CID: 71240010 5426 5504 26 CID: 71240011 5426 5504 27 CID: 11496366 5412 5420 28 CID: 11562021 5510 5492 29 CID: 11626824 5412 5420 30 CID: 11598102 5292 5294 31 CID: 11641497 5450 5138 32 CID: 11690598 4906 5138 33 CID: 68563708 4906 5138 34 CID: 11562217 5662 5908 35 CID: 11612136 5144 5032 36 CID: 58659130 5108 5294 37 CID: 11625675 4746 5052 38 CID: 67084493 4950 5334 39 CID: 11676204 4964 4962 40 CID: 11684380 4964 5424 41 CID: 59599446 5434 5704 42 CID: 11503318 5110 5138 43 CID: 11510387 5124 5372 44 CID: 11568619 5110 5138 45 CID: 11575401 4886 4826 46 CID: 11647760 5124 5372 47 CID: 58659136 5124 5372 48 CID: 72986690 5110 5138 49 CID: 11676140 4906 5484 50 CID: 58659141 5118 5278 51 CID: 11705849 5186 5370 52 CID: 11719356 5040 5238 53 CID: 11647759 5026 5118 54 CID: 21110753 5390 5526 55 CID: 21110757 4408 4604 56 CID: 73386634 4408 4604 57 CID: 11647795 5268 5212 Bold indicates the lead compounds showed higher binding score than crizotinib
table-wrap	Table 4 Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure S. no Compound ID Score 2XP2 4ANS 1 Crizotinib 5312 5226 2 CID: 11597571 5312 5226 3 CID: 11626560 5312 5226 4 CID: 53234260 5312 5226 5 CID: 53234326 5312 5226 6 CID: 56671814 5312 5226 7 CID: 60197531 5312 5226 8 CID: 60197626 5312 5226 9 CID: 60198523 5312 5226 10 CID: 60198524 5312 5226 11 CID: 60198525 5312 5226 12 CID: 60199015 5312 5226 13 CID: 60199016 5312 5226 14 CID: 60199073 5312 5226 15 CID: 60199075 5312 5226 16 CID: 60199076 5312 5226 17 CID: 60199077 5312 5226 18 CID: 62705017 5312 5226 19 CID: 68625002 5200 5342 20 CID: 54613769 5298 5308 21 CID: 11626823 5048 5226 22 CID: 44560358 5012 5386 23 CID: 71239831 5440 5776 24 CID: 71239833 5440 5776 25 CID: 71240010 5426 5504 26 CID: 71240011 5426 5504 27 CID: 11496366 5412 5420 28 CID: 11562021 5510 5492 29 CID: 11626824 5412 5420 30 CID: 11598102 5292 5294 31 CID: 11641497 5450 5138 32 CID: 11690598 4906 5138 33 CID: 68563708 4906 5138 34 CID: 11562217 5662 5908 35 CID: 11612136 5144 5032 36 CID: 58659130 5108 5294 37 CID: 11625675 4746 5052 38 CID: 67084493 4950 5334 39 CID: 11676204 4964 4962 40 CID: 11684380 4964 5424 41 CID: 59599446 5434 5704 42 CID: 11503318 5110 5138 43 CID: 11510387 5124 5372 44 CID: 11568619 5110 5138 45 CID: 11575401 4886 4826 46 CID: 11647760 5124 5372 47 CID: 58659136 5124 5372 48 CID: 72986690 5110 5138 49 CID: 11676140 4906 5484 50 CID: 58659141 5118 5278 51 CID: 11705849 5186 5370 52 CID: 11719356 5040 5238 53 CID: 11647759 5026 5118 54 CID: 21110753 5390 5526 55 CID: 21110757 4408 4604 56 CID: 73386634 4408 4604 57 CID: 11647795 5268 5212 Bold indicates the lead compounds showed higher binding score than crizotinib
label	Table 4
caption	Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure
p	Docking score of the crizotinib and lead compounds obtained from PubChem database against the target structure
table	S. no Compound ID Score 2XP2 4ANS 1 Crizotinib 5312 5226 2 CID: 11597571 5312 5226 3 CID: 11626560 5312 5226 4 CID: 53234260 5312 5226 5 CID: 53234326 5312 5226 6 CID: 56671814 5312 5226 7 CID: 60197531 5312 5226 8 CID: 60197626 5312 5226 9 CID: 60198523 5312 5226 10 CID: 60198524 5312 5226 11 CID: 60198525 5312 5226 12 CID: 60199015 5312 5226 13 CID: 60199016 5312 5226 14 CID: 60199073 5312 5226 15 CID: 60199075 5312 5226 16 CID: 60199076 5312 5226 17 CID: 60199077 5312 5226 18 CID: 62705017 5312 5226 19 CID: 68625002 5200 5342 20 CID: 54613769 5298 5308 21 CID: 11626823 5048 5226 22 CID: 44560358 5012 5386 23 CID: 71239831 5440 5776 24 CID: 71239833 5440 5776 25 CID: 71240010 5426 5504 26 CID: 71240011 5426 5504 27 CID: 11496366 5412 5420 28 CID: 11562021 5510 5492 29 CID: 11626824 5412 5420 30 CID: 11598102 5292 5294 31 CID: 11641497 5450 5138 32 CID: 11690598 4906 5138 33 CID: 68563708 4906 5138 34 CID: 11562217 5662 5908 35 CID: 11612136 5144 5032 36 CID: 58659130 5108 5294 37 CID: 11625675 4746 5052 38 CID: 67084493 4950 5334 39 CID: 11676204 4964 4962 40 CID: 11684380 4964 5424 41 CID: 59599446 5434 5704 42 CID: 11503318 5110 5138 43 CID: 11510387 5124 5372 44 CID: 11568619 5110 5138 45 CID: 11575401 4886 4826 46 CID: 11647760 5124 5372 47 CID: 58659136 5124 5372 48 CID: 72986690 5110 5138 49 CID: 11676140 4906 5484 50 CID: 58659141 5118 5278 51 CID: 11705849 5186 5370 52 CID: 11719356 5040 5238 53 CID: 11647759 5026 5118 54 CID: 21110753 5390 5526 55 CID: 21110757 4408 4604 56 CID: 73386634 4408 4604 57 CID: 11647795 5268 5212
tr	S. no Compound ID Score
th	S. no
th	Compound ID
th	Score
tr	2XP2 4ANS
th	2XP2
th	4ANS
tr	1 Crizotinib 5312 5226
td	1
td	Crizotinib
td	5312
td	5226
tr	2 CID: 11597571 5312 5226
td	2
td	CID: 11597571
td	5312
td	5226
tr	3 CID: 11626560 5312 5226
td	3
td	CID: 11626560
td	5312
td	5226
tr	4 CID: 53234260 5312 5226
td	4
td	CID: 53234260
td	5312
td	5226
tr	5 CID: 53234326 5312 5226
td	5
td	CID: 53234326
td	5312
td	5226
tr	6 CID: 56671814 5312 5226
td	6
td	CID: 56671814
td	5312
td	5226
tr	7 CID: 60197531 5312 5226
td	7
td	CID: 60197531
td	5312
td	5226
tr	8 CID: 60197626 5312 5226
td	8
td	CID: 60197626
td	5312
td	5226
tr	9 CID: 60198523 5312 5226
td	9
td	CID: 60198523
td	5312
td	5226
tr	10 CID: 60198524 5312 5226
td	10
td	CID: 60198524
td	5312
td	5226
tr	11 CID: 60198525 5312 5226
td	11
td	CID: 60198525
td	5312
td	5226
tr	12 CID: 60199015 5312 5226
td	12
td	CID: 60199015
td	5312
td	5226
tr	13 CID: 60199016 5312 5226
td	13
td	CID: 60199016
td	5312
td	5226
tr	14 CID: 60199073 5312 5226
td	14
td	CID: 60199073
td	5312
td	5226
tr	15 CID: 60199075 5312 5226
td	15
td	CID: 60199075
td	5312
td	5226
tr	16 CID: 60199076 5312 5226
td	16
td	CID: 60199076
td	5312
td	5226
tr	17 CID: 60199077 5312 5226
td	17
td	CID: 60199077
td	5312
td	5226
tr	18 CID: 62705017 5312 5226
td	18
td	CID: 62705017
td	5312
td	5226
tr	19 CID: 68625002 5200 5342
td	19
td	CID: 68625002
td	5200
td	5342
tr	20 CID: 54613769 5298 5308
td	20
td	CID: 54613769
td	5298
td	5308
tr	21 CID: 11626823 5048 5226
td	21
td	CID: 11626823
td	5048
td	5226
tr	22 CID: 44560358 5012 5386
td	22
td	CID: 44560358
td	5012
td	5386
tr	23 CID: 71239831 5440 5776
td	23
td	CID: 71239831
td	5440
td	5776
tr	24 CID: 71239833 5440 5776
td	24
td	CID: 71239833
td	5440
td	5776
tr	25 CID: 71240010 5426 5504
td	25
td	CID: 71240010
td	5426
td	5504
tr	26 CID: 71240011 5426 5504
td	26
td	CID: 71240011
td	5426
td	5504
tr	27 CID: 11496366 5412 5420
td	27
td	CID: 11496366
td	5412
td	5420
tr	28 CID: 11562021 5510 5492
td	28
td	CID: 11562021
td	5510
td	5492
tr	29 CID: 11626824 5412 5420
td	29
td	CID: 11626824
td	5412
td	5420
tr	30 CID: 11598102 5292 5294
td	30
td	CID: 11598102
td	5292
td	5294
tr	31 CID: 11641497 5450 5138
td	31
td	CID: 11641497
td	5450
td	5138
tr	32 CID: 11690598 4906 5138
td	32
td	CID: 11690598
td	4906
td	5138
tr	33 CID: 68563708 4906 5138
td	33
td	CID: 68563708
td	4906
td	5138
tr	34 CID: 11562217 5662 5908
td	34
td	CID: 11562217
td	5662
td	5908
tr	35 CID: 11612136 5144 5032
td	35
td	CID: 11612136
td	5144
td	5032
tr	36 CID: 58659130 5108 5294
td	36
td	CID: 58659130
td	5108
td	5294
tr	37 CID: 11625675 4746 5052
td	37
td	CID: 11625675
td	4746
td	5052
tr	38 CID: 67084493 4950 5334
td	38
td	CID: 67084493
td	4950
td	5334
tr	39 CID: 11676204 4964 4962
td	39
td	CID: 11676204
td	4964
td	4962
tr	40 CID: 11684380 4964 5424
td	40
td	CID: 11684380
td	4964
td	5424
tr	41 CID: 59599446 5434 5704
td	41
td	CID: 59599446
td	5434
td	5704
tr	42 CID: 11503318 5110 5138
td	42
td	CID: 11503318
td	5110
td	5138
tr	43 CID: 11510387 5124 5372
td	43
td	CID: 11510387
td	5124
td	5372
tr	44 CID: 11568619 5110 5138
td	44
td	CID: 11568619
td	5110
td	5138
tr	45 CID: 11575401 4886 4826
td	45
td	CID: 11575401
td	4886
td	4826
tr	46 CID: 11647760 5124 5372
td	46
td	CID: 11647760
td	5124
td	5372
tr	47 CID: 58659136 5124 5372
td	47
td	CID: 58659136
td	5124
td	5372
tr	48 CID: 72986690 5110 5138
td	48
td	CID: 72986690
td	5110
td	5138
tr	49 CID: 11676140 4906 5484
td	49
td	CID: 11676140
td	4906
td	5484
tr	50 CID: 58659141 5118 5278
td	50
td	CID: 58659141
td	5118
td	5278
tr	51 CID: 11705849 5186 5370
td	51
td	CID: 11705849
td	5186
td	5370
tr	52 CID: 11719356 5040 5238
td	52
td	CID: 11719356
td	5040
td	5238
tr	53 CID: 11647759 5026 5118
td	53
td	CID: 11647759
td	5026
td	5118
tr	54 CID: 21110753 5390 5526
td	54
td	CID: 21110753
td	5390
td	5526
tr	55 CID: 21110757 4408 4604
td	55
td	CID: 21110757
td	4408
td	4604
tr	56 CID: 73386634 4408 4604
td	56
td	CID: 73386634
td	4408
td	4604
tr	57 CID: 11647795 5268 5212
td	57
td	CID: 11647795
td	5268
td	5212
table-wrap-foot	Bold indicates the lead compounds showed higher binding score than crizotinib
p	Bold indicates the lead compounds showed higher binding score than crizotinib
p	It is also to be noted that the pharmacokinetic and pharmacodynamic investigation of CID 11562217 indicated better results than the other lead compounds explored in our study (Fig. 2). The two dimensional structure of crizotinib was compared with CID 11562217 to get the structural attributes and the result is demonstrated in Fig. 3. It demonstrates that CID11562217 is a nitrile enhanced crizotinib. It is worth stressing that nitrile compounds with cyanide functional group could possess potential anti-tumor effects (US Patent 20060128724). The literature evidence also highlights that our lead molecule has kinase inhibiting effects. Further, the cyano-containing analogues were able to produce DNA–DNA cross-linking. The reduced DNA cross-linking was paralleled by a similar reduction in cytotoxicity indicating a relationship between cross-linking and anti-tumor effect (Jesson et al. 1987). Therefore, further validation of CID 11562217 compound was done with the help of molecular dynamics simulation study. Fig. 2 Osiris property explorer showing drug-likeliness properties of CID11562217 Fig. 3 Structure comparison between (a) crizotinib and (b) CID11562217
figure	Fig. 2 Osiris property explorer showing drug-likeliness properties of CID11562217
label	Fig. 2
caption	Osiris property explorer showing drug-likeliness properties of CID11562217
p	Osiris property explorer showing drug-likeliness properties of CID11562217
figure	Fig. 3 Structure comparison between (a) crizotinib and (b) CID11562217
label	Fig. 3
caption	Structure comparison between (a) crizotinib and (b) CID11562217
p	Structure comparison between (a) crizotinib and (b) CID11562217
sec	Molecular dynamics simulation Molecular dynamics simulation study was carried out with the help of GROMACS package 4.5.3 to explore the stability of the complex structures. In particular, the parameter, RMSD, was examined from the trajectory file and used for analyzing the complex stability. RMSD investigation can give a thought of how much the three-dimensional structure has deviated over the time. The result is shown in Fig. 4. Native type ALK-crizotinib complex structure acquired ~0.34 nm at 1000 ps during the simulations, while mutant type ALK-crizotinib complex structure acquired ~0.28 nm of backbone RMSD at 1000 ps. On the other hand, native-type ALK-CID11562217 structure acquired ~0.18 nm of backbone RMSD while mutant-type ALK-CID11562217 complex structure acquired ~0.22 nm of backbone RMSD at 1000 ps. Between a period of 2000–5000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.30 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.25 to ~0.36 nm. In the virtual complex, native-type ALK-CID11562217 structure showed a RMSD value between ~0.18 and ~0.20 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.24 nm. From the period of 5000–10,000 ps, native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.34 nm while, mutant type ALK-crizotinib complex has deviated from ~0.32 to ~0.36 nm. On the contrary, native-type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm while mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.20 to ~0.24 nm. From the beginning of 11,000 ps to the end of 15,000 ps, mutant type ALK-crizotinib complex structure showed higher deviation and attains a RMSD value of ~0.44 nm while native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.23 nm. Mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm in this simulation period. Between a period of 16,000–19,000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.35 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.43 to ~0.45 nm. For instance, native-type ALK-CID11562217 structure showed a RMSD value of ~0.25 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.22 nm. At the end of 20,000 ps the mutant type ALK-crizotinib complex structure attained RMSD of ~0.40 nm and native type ALK-crizotinib complex structure attained RMSD of ~0.35 nm. This clearly indicates that ALK double mutation disturb the structural stability and also its function. It is worth stressing that native and mutant type ALK-CID 11562217 able to maintain a RMSD of ~0.24 nm. Overall, significant difference in RMSD value observed between the crizotinib and CID 11562217 complex system. The lesser RMSD value of CID 11562217 complex demonstrates the stable binding of CID 11562217 with both native and mutant type ALK structures. Fig. 4 Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K
title	Molecular dynamics simulation
p	Molecular dynamics simulation study was carried out with the help of GROMACS package 4.5.3 to explore the stability of the complex structures. In particular, the parameter, RMSD, was examined from the trajectory file and used for analyzing the complex stability. RMSD investigation can give a thought of how much the three-dimensional structure has deviated over the time. The result is shown in Fig. 4. Native type ALK-crizotinib complex structure acquired ~0.34 nm at 1000 ps during the simulations, while mutant type ALK-crizotinib complex structure acquired ~0.28 nm of backbone RMSD at 1000 ps. On the other hand, native-type ALK-CID11562217 structure acquired ~0.18 nm of backbone RMSD while mutant-type ALK-CID11562217 complex structure acquired ~0.22 nm of backbone RMSD at 1000 ps. Between a period of 2000–5000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.30 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.25 to ~0.36 nm. In the virtual complex, native-type ALK-CID11562217 structure showed a RMSD value between ~0.18 and ~0.20 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.24 nm. From the period of 5000–10,000 ps, native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.34 nm while, mutant type ALK-crizotinib complex has deviated from ~0.32 to ~0.36 nm. On the contrary, native-type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm while mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.20 to ~0.24 nm. From the beginning of 11,000 ps to the end of 15,000 ps, mutant type ALK-crizotinib complex structure showed higher deviation and attains a RMSD value of ~0.44 nm while native-type ALK-crizotinib complex structure maintains a RMSD value of ~0.23 nm. Mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.25 nm in this simulation period. Between a period of 16,000–19,000 ps, native type ALK-crizotinib complex structure maintains a RMSD value of ~0.35 nm whereas mutant type ALK-crizotinib complex structure showed a deviation from ~0.43 to ~0.45 nm. For instance, native-type ALK-CID11562217 structure showed a RMSD value of ~0.25 nm and mutant type ALK-CID11562217 complex structure maintains a RMSD value of ~0.22 nm. At the end of 20,000 ps the mutant type ALK-crizotinib complex structure attained RMSD of ~0.40 nm and native type ALK-crizotinib complex structure attained RMSD of ~0.35 nm. This clearly indicates that ALK double mutation disturb the structural stability and also its function. It is worth stressing that native and mutant type ALK-CID 11562217 able to maintain a RMSD of ~0.24 nm. Overall, significant difference in RMSD value observed between the crizotinib and CID 11562217 complex system. The lesser RMSD value of CID 11562217 complex demonstrates the stable binding of CID 11562217 with both native and mutant type ALK structures. Fig. 4 Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K
figure	Fig. 4 Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K
label	Fig. 4
caption	Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K
p	Root mean square deviations correspond to native-type ALK-crizotinib complex (black), mutant-type ALK-crizotinib complex (red), native-type ALK-CID11562217 complex (green) and mutant-type ALK-CID11562217 complex (blue) along the MD simulation at 300 K
sec	Conclusion In the present investigation, we have addressed the crizotinib resistance in NSCLC with the help of virtual screening approach. CID 11562217 was discovered to be more drug like as it productively passed through the parameters of pharmacokinetics and toxicity. Docking study demonstrated that CID 11562217 has the highest binding affinity not only with native type ALK but also with the mutant type ALK system among the lead compounds screened from the Pubchem database. RMSD data obtained from molecular dynamic simulation revealed structural stability of the ALK-CID11562217 complex structure. It is worth stressing that our results correlate well with available experimental evidences. Of note, the available data suggests that pyrazole-substituted aminoheteroaryl compounds have potential anti-tumor effects. We hope that the findings reported here might give helpful signs to design powerful drugs against drug resistant lung cancer types.
title	Conclusion
p	In the present investigation, we have addressed the crizotinib resistance in NSCLC with the help of virtual screening approach. CID 11562217 was discovered to be more drug like as it productively passed through the parameters of pharmacokinetics and toxicity. Docking study demonstrated that CID 11562217 has the highest binding affinity not only with native type ALK but also with the mutant type ALK system among the lead compounds screened from the Pubchem database. RMSD data obtained from molecular dynamic simulation revealed structural stability of the ALK-CID11562217 complex structure. It is worth stressing that our results correlate well with available experimental evidences. Of note, the available data suggests that pyrazole-substituted aminoheteroaryl compounds have potential anti-tumor effects. We hope that the findings reported here might give helpful signs to design powerful drugs against drug resistant lung cancer types.
back	The authors express a deep sense of gratitude to the Management of Vellore Institute of Technology for all the support, assistance and constant encouragement provided by them to carry out this work. Compliance with ethical standards Conflict of interest The authors declare that they have no conflict of interest.
ack	The authors express a deep sense of gratitude to the Management of Vellore Institute of Technology for all the support, assistance and constant encouragement provided by them to carry out this work.
p	The authors express a deep sense of gratitude to the Management of Vellore Institute of Technology for all the support, assistance and constant encouragement provided by them to carry out this work.
notes	Compliance with ethical standards Conflict of interest The authors declare that they have no conflict of interest.
title	Compliance with ethical standards
sec	Conflict of interest The authors declare that they have no conflict of interest.
title	Conflict of interest
p	The authors declare that they have no conflict of interest.

Annnotations TAB TSV DIC JSON TextAE

last updated at 2021-06-04 07:55:43 UTC

Denotations: 1
Blocks: 0
Relations: 0

PMC:4706832 / 10438-10442 JSONTXT

Document structure show

Annnotations TAB TSV DIC JSON TextAE

PMC:4706832 / 10438-10442 JSON TXT